| Year |
Citation |
Score |
| 2024 |
Joseph R, Dasari SK, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Kim MS, Corvigno S, Foster K, Hanjra P, ... ... Sood AK, et al. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. International Journal of Molecular Sciences. 25. PMID 38279277 DOI: 10.3390/ijms25021278 |
0.395 |
|
| 2023 |
Lutgendorf SK, Telles RM, Whitney B, Thaker PH, Slavich GM, Goodheart MJ, Penedo FJ, Noble AE, Cole SW, Sood AK, Corn BW. The biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients. Brain, Behavior, and Immunity. PMID 38081436 DOI: 10.1016/j.bbi.2023.12.014 |
0.369 |
|
| 2023 |
Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, et al. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. PMID 38009662 DOI: 10.1002/cncr.35126 |
0.305 |
|
| 2023 |
Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, ... ... Sood AK, et al. In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy. Npj Precision Oncology. 7: 115. PMID 37923835 DOI: 10.1038/s41698-023-00454-0 |
0.302 |
|
| 2023 |
Zhang X, Yao J, Li X, Niu N, Liu Y, Hajek RA, Peng G, Westin S, Sood AK, Liu J. Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Science Advances. 9: eadf7195. PMID 37478190 DOI: 10.1126/sciadv.adf7195 |
0.41 |
|
| 2023 |
Foster KI, Shaw KRM, Jin J, Westin SN, Yap TA, Glassman DM, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Ju Z, Liu Y, Fleming ND, Sood AK. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer. PMID 36930815 DOI: 10.1002/cncr.34724 |
0.361 |
|
| 2023 |
Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, ... ... Sood AK, et al. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. International Journal of Molecular Sciences. 24. PMID 36835335 DOI: 10.3390/ijms24043915 |
0.386 |
|
| 2023 |
Glassman D, Kim MS, Spradlin M, Badal S, Taki M, Bhattacharya P, Dutta P, Kingsley CV, Foster KI, Animasahun O, Jeon JH, Achreja A, Jayaraman A, Kumar P, Nenwani M, ... ... Sood AK, et al. Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. Iscience. 26: 106020. PMID 36824283 DOI: 10.1016/j.isci.2023.106020 |
0.304 |
|
| 2022 |
Ruiz M, Zhang N, Sood AK, An Z. Antibody therapeutics for epithelial ovarian cancer. Expert Opinion On Biological Therapy. 1-13. PMID 36302510 DOI: 10.1080/14712598.2022.2141565 |
0.323 |
|
| 2022 |
Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, ... ... Sood AK, et al. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. Jama Network Open. 5: e2236626. PMID 36239936 DOI: 10.1001/jamanetworkopen.2022.36626 |
0.375 |
|
| 2022 |
Glassman D, Bateman NW, Lee S, Zhao L, Yao J, Tan Y, Ivan C, Rangel KM, Zhang J, Conrads KA, Hood BL, Abulez T, Futreal PA, Fleming ND, Afshar-Kharghan V, ... ... Sood AK, et al. Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Cancers. 14. PMID 35326647 DOI: 10.3390/cancers14061496 |
0.362 |
|
| 2022 |
Wu Y, Jennings NB, Sun Y, Dasari SK, Bayraktar E, Corvigno S, Stur E, Glassman D, Mangala LS, Lankenau Ahumada A, Westin SN, Sood AK, Hu W. Targeting CCR2 macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. Journal of Cancer Research and Clinical Oncology. PMID 35094142 DOI: 10.1007/s00432-021-03885-z |
0.308 |
|
| 2021 |
Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, ... ... Sood AK, et al. Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature Medicine. PMID 34799731 DOI: 10.1038/s41591-021-01566-5 |
0.655 |
|
| 2021 |
Sasano T, Gonzalez-Delgado R, Muñoz NM, Carlos-Alcade W, Cho MS, Sheth RA, Sood AK, Afshar-Kharghan V. Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. Journal of Thrombosis and Haemostasis : Jth. PMID 34608736 DOI: 10.1111/jth.15544 |
0.355 |
|
| 2021 |
Niu N, Yao J, Bast RC, Sood AK, Liu J. IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis. 10: 65. PMID 34588424 DOI: 10.1038/s41389-021-00349-4 |
0.303 |
|
| 2021 |
Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim MS, Umamaheswaran S, Glassman D, Wen Y, ... ... Sood AK, et al. Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Molecular Cancer Therapeutics. PMID 34583979 DOI: 10.1158/1535-7163.MCT-21-0370 |
0.316 |
|
| 2021 |
Corvigno S, Burks JK, Hu W, Zhong Y, Jennings NB, Fleming ND, Westin SN, Fellman B, Liu J, Sood AK. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. Journal of Cancer Research and Clinical Oncology. PMID 34476576 DOI: 10.1007/s00432-021-03778-1 |
0.334 |
|
| 2021 |
Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, et al. Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. PMID 34433970 DOI: 10.1038/s41586-021-03664-3 |
0.307 |
|
| 2021 |
Lutgendorf SK, Ramirez E, Schrepf A, Valentine MC, Charlton M, Zimmerman MB, Goodheart MJ, Zia S, Sood AK, Thaker PH. Rural residence is related to shorter survival in epithelial ovarian cancer patients. Gynecologic Oncology. PMID 34400004 DOI: 10.1016/j.ygyno.2021.07.035 |
0.305 |
|
| 2021 |
Wu Y, Huang J, Ivan C, Sun Y, Ma S, Mangala LS, Fellman BM, Urbauer DL, Jennings NB, Ram P, Coleman RL, Hu W, Sood AK. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecologic Oncology. PMID 34391578 DOI: 10.1016/j.ygyno.2021.08.003 |
0.344 |
|
| 2021 |
Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MMK, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, ... ... Sood AK, et al. Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 27: 4454. PMID 34341059 DOI: 10.1158/1078-0432.CCR-21-2120 |
0.592 |
|
| 2021 |
Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MMK, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, ... Sood AK, et al. Editor's Note: Functional Roles of and in Ovarian Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 27: 4452. PMID 34341057 DOI: 10.1158/1078-0432.CCR-21-2118 |
0.574 |
|
| 2021 |
Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MMK, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, ... ... Sood AK, et al. Editor's Note: Targeting Src in Mucinous Ovarian Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 27: 4450. PMID 34341055 DOI: 10.1158/1078-0432.CCR-21-2116 |
0.588 |
|
| 2021 |
Saha B, Mathur T, Tronolone JJ, Chokshi M, Lokhande GK, Selahi A, Gaharwar AK, Afshar-Kharghan V, Sood AK, Bao G, Jain A. Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer. Science Advances. 7. PMID 34290095 DOI: 10.1126/sciadv.abg5283 |
0.364 |
|
| 2021 |
Cuneo MG, Szeto A, Schrepf A, Thaker PH, Goodheart M, Cole SW, Sood AK, McCabe PM, Mendez AJ, Lutgendorf SK. Positive Psychosocial Factors and Oxytocin in the Ovarian Tumor Microenvironment. Psychosomatic Medicine. 83: 417-422. PMID 34080583 DOI: 10.1097/PSY.0000000000000935 |
0.346 |
|
| 2021 |
Virani S, Baiocchi G, Bowtell D, Cabasag CJ, Cho KR, Fortner RT, Fujiwara K, Kim JW, Köbel M, Kurtz JE, Levine DA, Menon U, Norquist BM, Pharoah PDP, Sood AK, et al. Joint IARC/NCI International Cancer Seminar Series Report: Expert consensus on future directions for ovarian carcinoma research. Carcinogenesis. PMID 34037709 DOI: 10.1093/carcin/bgab043 |
0.347 |
|
| 2021 |
Lei G, Zhang Y, Hong T, Zhang X, Liu X, Mao C, Yan Y, Koppula P, Cheng W, Sood AK, Liu J, Gan B. Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. Oncogene. PMID 33927351 DOI: 10.1038/s41388-021-01790-w |
0.33 |
|
| 2021 |
Nitecki R, Fleming ND, Fellman BM, Meyer LA, Sood AK, Lu KH, Rauh-Hain JA. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology. PMID 33867146 DOI: 10.1016/j.ygyno.2021.04.012 |
0.328 |
|
| 2021 |
Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecologic Oncology. PMID 33838925 DOI: 10.1016/j.ygyno.2021.04.002 |
0.341 |
|
| 2021 |
Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, ... ... Sood AK, et al. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. Jci Insight. 6. PMID 33793425 DOI: 10.1172/jci.insight.149895 |
0.542 |
|
| 2021 |
Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, ... ... Sood AK, et al. ATP11B mediates platinum resistance in ovarian cancer. The Journal of Clinical Investigation. 131. PMID 33792569 DOI: 10.1172/JCI149893 |
0.323 |
|
| 2021 |
Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, ... ... Sood AK, et al. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecologic Oncology. PMID 33563487 DOI: 10.1016/j.ygyno.2020.12.010 |
0.341 |
|
| 2021 |
Patel A, Iyer P, Matsuzaki S, Matsuo K, Sood AK, Fleming ND. Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer. Cancers. 13. PMID 33562443 DOI: 10.3390/cancers13040626 |
0.342 |
|
| 2021 |
Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, ... ... Sood AK, et al. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecologic Oncology. PMID 33551196 DOI: 10.1016/j.ygyno.2021.01.022 |
0.305 |
|
| 2021 |
Karakuzu O, Tsimberidou AM, Holley VR, Adat A, Patel SP, Sood AK, Conley AP, Urschel GE, Healey DI, O'Neill V, Janku F. Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: Phase 2 basket study. Journal of Clinical Oncology. 39: 2558-2558. DOI: 10.1200/JCO.2021.39.15_SUPPL.2558 |
0.323 |
|
| 2021 |
Handley K, Sims T, Glassman D, Fleming N, Lee S, Fellman B, Yao H, Yao J, Liu J, Bast R, Lu Z, Westin S, Rangel K, Celestino J, Bateman N, ... ... Sood A, et al. If looks could kill: morphologic subtypes of high-grade serous ovarian cancer Gynecologic Oncology. 162: S20-S21. DOI: 10.1016/s0090-8258(21)00685-5 |
0.36 |
|
| 2020 |
Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, Cheon DJ, Fernández FM, Nephew KP, Karpf AR, ... Sood AK, et al. Targeting progesterone signaling prevents metastatic ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 33262282 DOI: 10.1073/pnas.2013595117 |
0.401 |
|
| 2020 |
Matsuo K, Matsuzaki S, Nusbaum DJ, Maoz A, Oda K, Klar M, Roman LD, Sood AK. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. Gynecologic Oncology. PMID 33196436 DOI: 10.1016/j.ygyno.2020.10.027 |
0.364 |
|
| 2020 |
Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, ... ... Sood AK, et al. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 33154095 DOI: 10.1136/ijgc-2020-001718 |
0.311 |
|
| 2020 |
Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AK. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. PMID 33149280 DOI: 10.1038/s41388-020-01517-3 |
0.414 |
|
| 2020 |
Kaur B, Hong B, Chapa V, Saini U, Modgil P, Cohn DE, He G, Siddik ZH, Sood AK, Yan Y, Karuppaiyah S, Pei G, Zhao Z, Yoo JY. Oncolytic HSV therapy modulates vesicular trafficking inducing cisplatin sensitivity and anti-tumor immunity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33087329 DOI: 10.1158/1078-0432.CCR-20-2210 |
0.302 |
|
| 2020 |
Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AK. Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer. Molecular Cancer Therapeutics. PMID 32943548 DOI: 10.1158/1535-7163.Mct-20-0030 |
0.374 |
|
| 2020 |
Cata JP, Sood AK, Eltzschig HK. Anesthetic Drugs and Cancer Progression: Fact or Fiction. Anesthesiology. PMID 32833387 DOI: 10.1097/Aln.0000000000003510 |
0.392 |
|
| 2020 |
Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK. Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget. 11: 2819-2833. PMID 32754300 DOI: 10.18632/Oncotarget.27667 |
0.445 |
|
| 2020 |
Wen Y, Wang Y, Chelariu-Raicu A, Stur E, Liu Y, Corvigno S, Bartsch F, Redfern L, Zand B, Kang Y, Liu J, Baggerly K, Sood AK. Blockade of the short-form of prolactin receptor induces FOXO3a/EIF-4EBP1-mediated cell death in uterine cancer. Molecular Cancer Therapeutics. PMID 32737156 DOI: 10.1158/1535-7163.Mct-19-1026 |
0.521 |
|
| 2020 |
Saha B, Mathur T, Handley KF, Hu W, Afshar-Kharghan V, Sood AK, Jain A. OvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer. Blood Advances. 4: 3329-3342. PMID 32717032 DOI: 10.1182/Bloodadvances.2020001632 |
0.425 |
|
| 2020 |
Lutgendorf SK, Penedo F, Goodheart MJ, Dahmoush L, Arevalo JMG, Thaker PH, Slavich GM, Sood AK, Cole SW. Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation. Cancer. PMID 32691853 DOI: 10.1002/Cncr.33060 |
0.386 |
|
| 2020 |
Li Y, Yang S, Sadaoui NC, Hu W, Dasari SK, Mangala LS, Sun Y, Zhao S, Wang L, Liu Y, Ramondetta LM, Li K, Lu C, Kang Y, Cole SW, ... ... Sood AK, et al. Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells. Iscience. 23: 101289. PMID 32623336 DOI: 10.1016/J.Isci.2020.101289 |
0.485 |
|
| 2020 |
Matsuo K, Huang Y, Matsuzaki S, Klar M, Roman LD, Sood AK, Wright JD. Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer. Jama Oncology. PMID 32525512 DOI: 10.1001/Jamaoncol.2020.1702 |
0.374 |
|
| 2020 |
Miyake TM, Pradeep S, Bayraktar E, Stur E, Handley KF, Wu SY, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AK. NRG1/ERBB3 pathway activation induces acquired resistance to XPO1 inhibitors. Molecular Cancer Therapeutics. PMID 32499298 DOI: 10.1158/1535-7163.Mct-19-0977 |
0.466 |
|
| 2020 |
Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, ... ... Sood AK, et al. Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nature Communications. 11: 2867. PMID 32493919 DOI: 10.1038/S41467-020-16661-3 |
0.578 |
|
| 2020 |
Maoz A, Matsuo K, Ciccone MA, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DM. Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review. Cancers. 12. PMID 32485873 DOI: 10.3390/Cancers12061398 |
0.427 |
|
| 2020 |
Matsuo K, Chang EJ, Matsuzaki S, Mandelbaum RS, Matsushima K, Grubbs BH, Klar M, Roman LD, Sood AK, Wright JD. Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes. Gynecologic Oncology. PMID 32402635 DOI: 10.1016/J.Ygyno.2020.04.045 |
0.351 |
|
| 2020 |
Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, ... ... Sood AK, et al. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Reports. 31: 107502. PMID 32294438 DOI: 10.1016/J.Celrep.2020.03.066 |
0.396 |
|
| 2020 |
Wi TI, Byeon Y, Won JE, Lee JM, Kang TH, Lee JW, Lee YJ, Sood AK, Han HD, Park YM. Selective Tumor-Specific Antigen Delivery to Dendritic Cells Using Mannose-Labeled Poly(d, l-lactide-co-glycolide) Nanoparticles for Cancer Immunotherapy. Journal of Biomedical Nanotechnology. 16: 201-211. PMID 32252881 DOI: 10.1166/Jbn.2020.2883 |
0.334 |
|
| 2020 |
Salcedo MP, Sood AK, Jhingran A, Eifel PJ, Klopp AH, Iyer RB, Felllman BM, Jimenez C, Schmeler KM. Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. Cancer. PMID 32125711 DOI: 10.1002/Cncr.32807 |
0.303 |
|
| 2020 |
Cao Q, Wang W, Zhou M, Huang Q, Wen X, Zhao J, Shi S, Geng K, Li F, Hatakeyama H, Xu C, Piwnica-Worms D, Peng W, Zhou D, Sood AK, et al. Induction of antitumor immunity in mice by the combination of nanoparticle-based Photothermolysis and anti-PD-1 checkpoint inhibition. Nanomedicine : Nanotechnology, Biology, and Medicine. 102169. PMID 32059873 DOI: 10.1016/J.Nano.2020.102169 |
0.334 |
|
| 2020 |
Coleman RL, Handley KF, Burger R, Molin GZD, Stagg R, Sood AK, Moore KN. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. Gynecologic Oncology. PMID 32037195 DOI: 10.1016/J.Ygyno.2020.01.042 |
0.391 |
|
| 2020 |
Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, ... ... Sood AK, et al. Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112]. Ebiomedicine. 52: 102630. PMID 31972470 DOI: 10.1016/J.Ebiom.2020.102630 |
0.349 |
|
| 2020 |
Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, et al. Low-grade serous ovarian cancer: State of the science. Gynecologic Oncology. PMID 31969252 DOI: 10.1016/J.Ygyno.2019.12.033 |
0.351 |
|
| 2020 |
Xiong C, Wen Y, Zhao J, Yin D, Xu L, Chelariu-Raicu A, Yao C, Leng X, Liu J, Chaudhari RR, Zhang S, Sood AK, Li C. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions. Scientific Reports. 10: 520. PMID 31949258 DOI: 10.1038/S41598-020-57477-X |
0.416 |
|
| 2020 |
El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cellular Signalling. 109539. PMID 31935430 DOI: 10.1016/J.Cellsig.2020.109539 |
0.497 |
|
| 2020 |
Stur E, Molin GZD, Wu S, Baggerly K, Tworoger S, Levine D, Karlan B, Moore K, Lutgendorf S, Sood A. Abstract A26: Molecular analysis of short- vs. long-term ovarian cancer survivors Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Ovca19-A26 |
0.472 |
|
| 2020 |
Niu N, Li X, Yao J, Sood A, Liu J. Abstract A17: Polyploid giant cancer cells lead to evolution of drug resistance in high-grade ovarian cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-A17 |
0.425 |
|
| 2020 |
Westin SN, Lee S, Zhao L, Yuan Y, Wu J, Hajek R, Sharafi S, Meyer LA, Fleming ND, Jazaeri A, Coleman RL, Lu KH, Mills GB, Zhang J, Futreal A, ... Sood AK, et al. Abstract CT188: Pharmacodynamic changes by durvalumab in combination with chemotherapy in women with untreated, advanced stage ovarian cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2020-Ct188 |
0.367 |
|
| 2020 |
Naing A, Karp D, Piha-Paul SA, Pant S, Subbiah V, Bodurka DC, Fu S, Jazaeri AA, Kato S, Schmeler K, Nick A, Yang Y, Akhmedzhanov FO, Fessahaye S, Gong J, ... ... Sood AK, et al. Abstract CT163: Temsirolimus in combinaton with metformin in patients with advanced or refractory endometrial cancers Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct163 |
0.394 |
|
| 2020 |
Ma S, Mangala LS, Hu W, Bayaktar E, Hu W, Jennings NB, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 6331: Cloaking VEGF in small extracellular vesicles as a cause of adaptive resistance to anti-VEGF therapy Cancer Research. 80: 6331-6331. DOI: 10.1158/1538-7445.Am2020-6331 |
0.389 |
|
| 2020 |
Umamaheswaran S, Dasari SK, Yokoi A, Stur E, Sood AK. Abstract 6202: Effect of sympathetic nervous system mediators on the tumor microenvironment via small extracellular vesicles in ovarian cancer Cancer Research. 80: 6202-6202. DOI: 10.1158/1538-7445.Am2020-6202 |
0.46 |
|
| 2019 |
Matsuo K, Machida H, Grubbs BH, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DM. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. Gynecologic Oncology. PMID 31954535 DOI: 10.1016/J.Ygyno.2019.08.030 |
0.484 |
|
| 2019 |
Matsuo K, Machida H, Matsuzaki S, Grubbs BH, Klar M, Roman LD, Sood AK, Gershenson DM, Wright JD. Evolving population-based statistics for rare epithelial ovarian cancers. Gynecologic Oncology. PMID 31954534 DOI: 10.1016/J.Ygyno.2019.11.122 |
0.414 |
|
| 2019 |
Seiler A, Sood AK, Jenewein J, Fagundes CP. Can stress promote the pathophysiology of brain metastases? A critical review of biobehavioral mechanisms. Brain, Behavior, and Immunity. PMID 31881262 DOI: 10.1016/J.Bbi.2019.12.013 |
0.386 |
|
| 2019 |
Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, ... ... Sood AK, et al. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Reports. 29: 4389-4406.e10. PMID 31875548 DOI: 10.1016/J.Celrep.2019.11.085 |
0.409 |
|
| 2019 |
Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G. Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. Rna Biology. 1-12. PMID 31847695 DOI: 10.1080/15476286.2019.1702283 |
0.44 |
|
| 2019 |
Peres LC, Sinha S, Townsend MK, Fridley BL, Karlan BY, Lutgendorf SK, Shinn E, Sood AK, Tworoger SS. Predictors of survival trajectories among women with epithelial ovarian cancer. Gynecologic Oncology. PMID 31839342 DOI: 10.1016/J.Ygyno.2019.12.011 |
0.397 |
|
| 2019 |
Yokoi A, Villar-Prados A, Oliphint PA, Zhang J, Song X, De Hoff P, Morey R, Liu J, Roszik J, Clise-Dwyer K, Burks JK, O'Halloran TJ, Laurent LC, Sood AK. Mechanisms of nuclear content loading to exosomes. Science Advances. 5: eaax8849. PMID 31799396 DOI: 10.1126/Sciadv.Aax8849 |
0.395 |
|
| 2019 |
Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, ... ... Sood AK, et al. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Scientific Reports. 9: 17589. PMID 31772388 DOI: 10.1038/S41598-019-53872-1 |
0.372 |
|
| 2019 |
Sa JK, Hwang JR, Cho YJ, Ryu JY, Choi JJ, Jeong SY, Kim J, Kim MS, Paik ES, Lee YY, Choi CH, Kim TJ, Kim BG, Bae DS, Lee Y, ... ... Sood AK, et al. Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. Genome Biology. 20: 253. PMID 31771620 DOI: 10.1186/S13059-019-1848-3 |
0.417 |
|
| 2019 |
Kurnit KC, Sinno AK, Fellman BM, Varghese A, Stone R, Sood AK, Gershenson DM, Schmeler KM, Malpica A, Fader AN, Frumovitz M. Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma. Obstetrics and Gynecology. 134: 1253-1259. PMID 31764736 DOI: 10.1097/Aog.0000000000003579 |
0.301 |
|
| 2019 |
Lara OD, Wang Y, Asare A, Xu T, Chiu HS, Liu Y, Hu W, Sumazin P, Uppal S, Zhang L, Rauh-Hain JA, Sood AK. Pan-cancer clinical and molecular analysis of racial disparities. Cancer. PMID 31730714 DOI: 10.1002/Cncr.32598 |
0.383 |
|
| 2019 |
Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Tsang YH, Rodriguez-Aguayo C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang H. A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. The Journal of Clinical Investigation. PMID 31682236 DOI: 10.1172/Jci123396 |
0.384 |
|
| 2019 |
Handley KF, Sood AK. A solution to the dilution: The role for biomarkers in advanced ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31672769 DOI: 10.1158/1078-0432.Ccr-19-3072 |
0.331 |
|
| 2019 |
Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, Lee JS, Kwon SY, Cho CH, Kim J, Coleman RL, Lopez-Bernstein G, Sood AK. Clinical and biological significance of expression in endometrial cancer. Cancer Biology & Therapy. 1-10. PMID 31640461 DOI: 10.1080/15384047.2019.1672455 |
0.5 |
|
| 2019 |
Trudel-Fitzgerald C, Poole EM, Sood AK, Okereke OI, Kawachi I, Kubzansky LD, Tworoger SS. Social integration, marital status, and ovarian cancer risk: A 20-year prospective cohort study. Psychosomatic Medicine. PMID 31592935 DOI: 10.1097/Psy.0000000000000747 |
0.394 |
|
| 2019 |
Shi S, Li T, Wen X, Wu SY, Xiong C, Zhao J, Lincha VR, Chow DS, Liu Y, Sood AK, Li C. Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention. Bioconjugate Chemistry. PMID 31560538 DOI: 10.1021/Acs.Bioconjchem.9B00587 |
0.34 |
|
| 2019 |
Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, ... ... Sood AK, et al. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31391192 DOI: 10.1158/1078-0432.Ccr-18-3448 |
0.46 |
|
| 2019 |
Shuford S, Wilhelm C, Rayner M, Elrod A, Millard M, Mattingly C, Lotstein A, Smith AM, Guo QJ, O'Donnell L, Elder J, Puls L, Weroha SJ, Hou X, Zanfagnin V, ... ... Sood AK, et al. Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer. Scientific Reports. 9: 11153. PMID 31371750 DOI: 10.1038/S41598-019-47578-7 |
0.366 |
|
| 2019 |
Chelariu-Raicu A, Coleman RL, Sood AK. Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit? Oncology (Williston Park, N.Y.). 33. PMID 31365748 |
0.364 |
|
| 2019 |
Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, ... Sood AK, et al. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecologic Oncology. PMID 31353053 DOI: 10.1016/J.Ygyno.2019.07.004 |
0.436 |
|
| 2019 |
Bach DH, Zhang W, Sood AK. Chromosomal Instability in Tumor Initiation and Development. Cancer Research. PMID 31350294 DOI: 10.1158/0008-5472.Can-18-3235 |
0.4 |
|
| 2019 |
Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, ... ... Sood AK, et al. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene. PMID 31289363 DOI: 10.1038/S41388-019-0862-Y |
0.385 |
|
| 2019 |
Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, et al. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 10: 3533-3546. PMID 31191824 DOI: 10.18632/Oncotarget.26947 |
0.303 |
|
| 2019 |
Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ. Advancing Drug Development in Gynecologic Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31126961 DOI: 10.1158/1078-0432.Ccr-19-0619 |
0.414 |
|
| 2019 |
Park YY, Yun Jung S, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Bae Kim S, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. PMID 31063534 DOI: 10.1093/Carcin/Bgz062 |
0.331 |
|
| 2019 |
Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, ... Sood AK, et al. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer. PMID 31012964 DOI: 10.1002/Cncr.32053 |
0.392 |
|
| 2019 |
Cuneo MG, Szeto A, Schrepf A, Kinner EM, Schachner BI, Ahmed R, Thaker PH, Goodheart M, Bender D, Cole SW, McCabe PM, Sood AK, Lutgendorf SK, Mendez AJ. Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. Psychoneuroendocrinology. 106: 244-251. PMID 31005045 DOI: 10.1016/J.Psyneuen.2019.04.007 |
0.501 |
|
| 2019 |
Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, ... Sood AK, et al. GnRH-R targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition. Molecular Cancer Therapeutics. PMID 30926640 DOI: 10.1158/1535-7163.Mct-18-0770 |
0.456 |
|
| 2019 |
Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, et al. Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. Oncogene. PMID 30918328 DOI: 10.1038/S41388-019-0786-6 |
0.439 |
|
| 2019 |
Bach DH, Lee SK, Sood AK. Circular RNAs in Cancer. Molecular Therapy. Nucleic Acids. 16: 118-129. PMID 30861414 DOI: 10.1016/J.Omtn.2019.02.005 |
0.385 |
|
| 2019 |
Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, et al. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. PMID 30835824 DOI: 10.1002/Cncr.32004 |
0.466 |
|
| 2019 |
Matsuo K, Machida H, Mandelbaum RS, Grubbs BH, Roman LD, Sood AK, Gershenson DM. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. Gynecologic Oncology. PMID 30797590 DOI: 10.1016/J.Ygyno.2019.02.003 |
0.462 |
|
| 2019 |
Sans M, Zhang J, Lin JQ, Feider CL, Giese N, Breen MT, Sebastian K, Liu J, Sood AK, Eberlin LS. Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer. Clinical Chemistry. PMID 30770374 DOI: 10.1373/Clinchem.2018.299289 |
0.388 |
|
| 2019 |
Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, ... ... Sood AK, et al. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. Ebiomedicine. PMID 30655206 DOI: 10.1016/J.Ebiom.2018.11.045 |
0.425 |
|
| 2019 |
LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. The Lancet. Oncology. 20: e15-e28. PMID 30614472 DOI: 10.1016/S1470-2045(18)30786-1 |
0.384 |
|
| 2019 |
Fleming ND, Westin SN, Meyer L, Rauh-Hain JA, Shafer A, Onstad M, Cobb LP, Bevers MW, Burzawa JK, Zand B, Fellman BM, Jazaeri AA, Levenback CF, Coleman RL, Soliman PT, ... Sood AK, et al. Correlation of surgeon radiology assessment with laparoscopic scoring in patients with advanced-stage ovarian cancer. Journal of Clinical Oncology. 37: 5570-5570. DOI: 10.1200/Jco.2019.37.15_Suppl.5570 |
0.392 |
|
| 2019 |
Harrison R, Cantor SB, Villanueva M, Suidan RS, Sun CC, Rauh-Hain JA, Westin SN, Fleming ND, Sood AK, Lu KH, Meyer L. Cost-effectiveness analysis of laparoscopic disease assessment in ovarian cancer. Journal of Clinical Oncology. 37: 5556-5556. DOI: 10.1200/Jco.2019.37.15_Suppl.5556 |
0.375 |
|
| 2019 |
Shuford S, Elder J, Puls L, Weroha J, Hou X, Zanfagnin V, Nick A, Stany MP, Maxwell L, Conrads T, Corless C, Sood AK, Gevaert M, Crosswell HE, DesRochers TM. Abstract TMIM-069: PROSPECTIVE CLINICAL VALIDATION OF EX VIVO, PATIENT-SPECIFIC RESPONSE PREDICTION TO FIRST-LINE CHEMOTHERAPY Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Tmim-069 |
0.428 |
|
| 2019 |
Thiviyanathan V, Pi F, Zhang H, Li H, Wang H, Guo P, Sood A. Abstract NT-112: APTAMER CONJUGATED NANOPARTICLES FOR TARGETED DRUG DELIVERY Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Nt-112 |
0.408 |
|
| 2019 |
Wen Y, Wang Y, Ma S, Raicu AC, Baggerly KA, Sood AK. Abstract 3720: Blockade of the short-form of prolactin receptor induces FOXO3a/EIF-4EBP1-mediated cell death in uterine cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3720 |
0.387 |
|
| 2019 |
Rodriguez-Aguayo C, Bayraktar E, Mangala LS, Ivan C, Lopez-Berestein G, Sood AK. Abstract 3579: Long non-coding RNA ADAMTS9-AS2 inhibits ovarian tumor growth via Annexin A1 Cancer Research. 79: 3579-3579. DOI: 10.1158/1538-7445.Sabcs18-3579 |
0.463 |
|
| 2019 |
Kim MS, Ma S, Leuschner C, Lee S, Coleman RL, Sood AK. Abstract 3199: Targeting LHRH-R to improve immune response in ovarian cancer Immunology. DOI: 10.1158/1538-7445.Sabcs18-3199 |
0.376 |
|
| 2019 |
Ma S, McGuire MH, Stur E, Bayraktar E, Villar-Prados A, Wu SY, Yokoi A, Dasari SK, Rodriguez-Aguayo C, Liu J, Lopez-Berestein G, Sood AK. Abstract LB-311: Exosomal gain-of-function p53 protein promotes cancer-associated phenotype Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-311 |
0.461 |
|
| 2019 |
Yokoi A, Villar-Prados A, Oliphint PA, O'Halloran TJ, Roszik J, Sood AK. Abstract LB-232: A novel approach for liquid biopsy by using nExo Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-232 |
0.481 |
|
| 2019 |
Kurnit KC, Meric-Bernstam F, Hess K, Coleman RL, Bhosale P, Savelieva K, Janku F, Hong D, Naing A, Pant S, Rodon J, Yap TA, Sood AK, Soliman PT, Gershenson DM, et al. Abstract CT020: Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct020 |
0.39 |
|
| 2019 |
Lara OD, Wang Y, Hu W, Zhang L, Rauh-Hain A, Sood A. Abstract 4205: Pan-cancer molecular study of disparities among African Americans Cancer Research. 79: 4205-4205. DOI: 10.1158/1538-7445.Am2019-4205 |
0.46 |
|
| 2019 |
Joseph R, Soundararajan R, Vasaikar S, Yang F, Isgandarova S, Tian L, Haemmerle M, Mino B, Zhou T, Raja GV, Pena ER, Hollander PD, Bhangre N, Shin C, Martinez M, ... ... Sood A, et al. Abstract 3761: Regulation of metastasis by CD8 T lymphocytes Cancer Research. 79: 3761-3761. DOI: 10.1158/1538-7445.Am2019-3761 |
0.467 |
|
| 2019 |
Labrie M, Ju Z, Litton JK, Kim T, Lee S, Chen K, Soliman PT, Frumovitz M, Meyer LA, Moulder S, Jazaeri AA, Lu KH, Sood AK, Coleman RL, Mills GB, et al. Abstract 2070: Exploration of markers of synergistic lethality of PARP and PI3K-Akt-mTOR inhibitors in women's cancers Cancer Research. 79: 2070-2070. DOI: 10.1158/1538-7445.Am2019-2070 |
0.384 |
|
| 2019 |
LaFargue CJ, Amero P, Noh K, Mangala S, Lu C, Cho M, Pradeep S, Wan Y, Hu W, Rupaimoole R, Coleman RL, Zhang N, An Z, Lopez-Bernstein G, Franciscis Vd, ... Sood AK, et al. Abstract 194: Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L Cancer Research. 79: 194-194. DOI: 10.1158/1538-7445.Am2019-194 |
0.437 |
|
| 2019 |
Kurnit KC, Sinno AK, Fellman B, Stone RL, Sood AK, Gershenson DM, Schmeler KM, Fader AN, Frumovitz M. Gastrointestinal adjuvant chemotherapy regimens improve survival outcomes in women with mucinous ovarian cancer Gynecologic Oncology. 154: 248-249. DOI: 10.1016/J.Ygyno.2019.04.573 |
0.381 |
|
| 2019 |
Cobb LP, Fellman B, Gershenson DM, Sood AK, Nick AM, Westin SN, Coleman RL, Fleming ND. The use of a laparoscopic surgical algorithm to triage the timing of cytoreductive surgery in patients with low grade serous ovarian and peritoneal cancer Gynecologic Oncology. 154: 247. DOI: 10.1016/J.Ygyno.2019.04.570 |
0.344 |
|
| 2019 |
Molin GD, Sood A, Fellman B, Coleman R, Westin S, Meyer L, Fleming N. Assessment of survival after primary treatment in ovarian cancer patients using a modified frailty index Gynecologic Oncology. 154: 209. DOI: 10.1016/J.YGYNO.2019.04.484 |
0.305 |
|
| 2019 |
LaFargue C, Fleming N, Nick A, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom M, Blake E, Crim A, Westin S, Coleman R, Matsuo K, Hasegawa K, Moore K, ... Sood A, et al. Diamonds in the rough: An analysis of complete pathologic responders in ovarian cancer Gynecologic Oncology. 154: 176. DOI: 10.1016/J.YGYNO.2019.04.409 |
0.346 |
|
| 2019 |
Lara OD, Wang Y, Zhang L, Hu W, Rauh-Hain JA, Sood AK. Think outside the box: Pan-cancer molecular study of gynecologic disparities among African Americans Gynecologic Oncology. 154: 117. DOI: 10.1016/J.Ygyno.2019.04.279 |
0.382 |
|
| 2019 |
LaFargue C, Villar-Prados A, Ivan C, Strovel J, Sood A. Becoming a BET inhibitor 'sommelier': Identifying the best combinations for ovarian cancer Gynecologic Oncology. 154: 68. DOI: 10.1016/J.YGYNO.2019.04.161 |
0.348 |
|
| 2019 |
Villar-Prados A, Ma S, LaFargue C, Roszik J, Sood AK. Predicting novel therapies and targets in ovarian and uterine cancers Gynecologic Oncology. 154: 63-64. DOI: 10.1016/J.Ygyno.2019.04.150 |
0.423 |
|
| 2019 |
Labrie M, Ju Z, Litton JK, Kim TB, Lee S, Chen K, Soliman PT, Frumovitz M, Meyer LA, Moulder S, Jazaeri AA, Lu KH, Sood AK, Coleman RL, Mills GB, et al. Exploration of markers of synergistic lethality of PARP and PI3K-akt-mTOR inhibitors in women’s cancers Gynecologic Oncology. 154: 60. DOI: 10.1016/J.Ygyno.2019.04.143 |
0.408 |
|
| 2018 |
Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley K, Isidoro C, Sood AK, Song YS, Dhanasekaran DN. Ovarian Cancer Cell-derived Lysophosphatidic Acid Induces Glycolytic Shift and Cancer-associated Fibroblast-Phenotype in Normal and Peritumoral Fibroblasts. Cancer Letters. PMID 30503552 DOI: 10.1016/J.Canlet.2018.11.023 |
0.496 |
|
| 2018 |
An J, Du Y, Fan X, Wang Y, Ivan C, Zhang XG, Sood AK, An Z, Zhang N. EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. Oncogene. PMID 30455428 DOI: 10.1038/S41388-018-0565-9 |
0.511 |
|
| 2018 |
Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Yang SM, Maloney DJ, ... ... Sood AK, et al. Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4. Molecular Cancer Therapeutics. PMID 30420565 DOI: 10.1158/1535-7163.Mct-18-0365 |
0.364 |
|
| 2018 |
Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecologic Oncology. PMID 30366647 DOI: 10.1016/J.Ygyno.2018.10.017 |
0.412 |
|
| 2018 |
Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, ... ... Sood AK, et al. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Molecular Cancer Therapeutics. PMID 30305341 DOI: 10.1158/1535-7163.Mct-17-1050 |
0.409 |
|
| 2018 |
Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, Hu X, Zhang Y, Wang Y, Jiang J, Li C, Zhong X, Montone KT, Guan G, Tanyi JL, ... ... Sood AK, et al. Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell. 34: 549-560.e9. PMID 30300578 DOI: 10.1016/J.Ccell.2018.08.019 |
0.4 |
|
| 2018 |
Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, et al. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecologic Oncology. PMID 30213435 DOI: 10.1016/J.Ygyno.2018.08.037 |
0.362 |
|
| 2018 |
Zhang L, Peng D, Sood AK, Dang CV, Zhong X. Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer. Molecular Cancer Therapeutics. 17: 1816-1823. PMID 30181330 DOI: 10.1158/1535-7163.Mct-18-0124 |
0.431 |
|
| 2018 |
Byeon Y, Lee JW, Choi WS, Won JE, Kim GH, Kim MG, Wi TI, Lee JM, Kang TH, Jung ID, Cho YJ, Ahn HJ, Shin BC, Lee YJ, Sood AK, et al. CD44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer. Cancer Research. PMID 30115698 DOI: 10.1158/0008-5472.Can-17-3871 |
0.411 |
|
| 2018 |
Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Reviews. PMID 30112590 DOI: 10.1007/S10555-018-9755-8 |
0.366 |
|
| 2018 |
Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstetrics and Gynecology. PMID 30095787 DOI: 10.1097/Aog.0000000000002796 |
0.386 |
|
| 2018 |
Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Artholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30084832 DOI: 10.1158/1078-0432.Ccr-18-0504 |
0.346 |
|
| 2018 |
Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, ... Sood AK, et al. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications. 9: 2923. PMID 30050129 DOI: 10.1038/S41467-018-04987-Y |
0.497 |
|
| 2018 |
Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 30036226 DOI: 10.1097/Igc.0000000000001329 |
0.484 |
|
| 2018 |
González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martin-Salvago MD, Luque RJ, ... ... Sood AK, et al. Activating transcription factor 4 modulates TGFβ-induced aggressiveness in triple negative breast cancer via SMAD2/3/4 and mTORC2 signaling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30012564 DOI: 10.1158/1078-0432.Ccr-17-3125 |
0.39 |
|
| 2018 |
Dal Molin GZ, Omatsu K, Sood AK, Coleman RL. Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Therapeutic Advances in Medical Oncology. 10: 1758835918778483. PMID 29977351 DOI: 10.1177/1758835918778483 |
0.398 |
|
| 2018 |
Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, ... Sood AK, et al. Stress effects on FosB and interleukin-8 ()-driven ovarian cancer growth and metastasis. The Journal of Biological Chemistry. 293: 10041. PMID 29959278 DOI: 10.1074/Jbc.Aac118.004299 |
0.708 |
|
| 2018 |
Umamaheswaran S, Dasari SK, Yang P, Lutgendorf SK, Sood AK. Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Reviews. PMID 29948328 DOI: 10.1007/S10555-018-9741-1 |
0.303 |
|
| 2018 |
Armer JS, Clevenger L, Davis LZ, Cuneo M, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Sood AK, Cole SW, Slavich GM, Lutgendorf SK. Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer. PMID 29905941 DOI: 10.1002/Cncr.31570 |
0.406 |
|
| 2018 |
Kim GH, Won JE, Byeon Y, Kim MG, Wi TI, Lee JM, Park YY, Lee JW, Kang TH, Jung ID, Shin BC, Ahn HJ, Lee YJ, Sood AK, Han HD, et al. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Drug Delivery. 25: 1394-1402. PMID 29890852 DOI: 10.1080/10717544.2018.1480672 |
0.355 |
|
| 2018 |
Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, ... ... Sood AK, et al. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. Jci Insight. 3. PMID 29889660 DOI: 10.1172/jci.insight.122389 |
0.542 |
|
| 2018 |
Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AK. ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget. 9: 25115-25126. PMID 29861857 DOI: 10.18632/Oncotarget.25344 |
0.488 |
|
| 2018 |
Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. Jama Oncology. PMID 29860375 DOI: 10.1001/Jamaoncol.2018.2761 |
0.317 |
|
| 2018 |
Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, ... ... Sood AK, et al. ATP11B mediates platinum resistance in ovarian cancer. The Journal of Clinical Investigation. PMID 29809169 DOI: 10.1172/Jci122301 |
0.471 |
|
| 2018 |
Haldar R, Shaashua L, Lavon H, Lyons YA, Zmora O, Sharon E, Birnbaum Y, Allweis T, Sood AK, Barshack I, Cole S, Ben-Eliyahu S. Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. Brain, Behavior, and Immunity. PMID 29800703 DOI: 10.1016/J.Bbi.2018.05.014 |
0.363 |
|
| 2018 |
Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, ... ... Sood AK, et al. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Reports. 23: 823-837. PMID 29669287 DOI: 10.1016/J.Celrep.2018.03.078 |
0.451 |
|
| 2018 |
Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemerrle M, Gharpure KM, Rupaimoole R, Previs R, Wu SY, Pradeep S, Xu X, ... ... Sood AK, et al. Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction. Cancer Research. PMID 29661830 DOI: 10.1158/0008-5472.Can-16-1701 |
0.68 |
|
| 2018 |
Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell. PMID 29657130 DOI: 10.1016/J.Ccell.2018.03.002 |
0.436 |
|
| 2018 |
Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, ... ... Sood AK, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. PMID 29622464 DOI: 10.1016/J.Ccell.2018.03.014 |
0.404 |
|
| 2018 |
Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS, Sood AK, Gunaratne PH, Sumazin P. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Reports. 23: 297-312.e12. PMID 29617668 DOI: 10.1016/J.Celrep.2018.03.064 |
0.499 |
|
| 2018 |
Vu HT, Kotla S, Ko KA, Fujii Y, Tao Y, Medina J, Thomas T, Hada M, Sood AK, Singh PK, Milgrom SA, Krishnan S, Fujiwara K, Le NT, Abe JI. Ionizing Radiation Induces Endothelial Inflammation and Apoptosis via p90RSK-Mediated ERK5 S496 Phosphorylation. Frontiers in Cardiovascular Medicine. 5: 23. PMID 29594152 DOI: 10.3389/Fcvm.2018.00023 |
0.32 |
|
| 2018 |
Ma S, Pradeep S, Hu W, Zhang D, Coleman R, Sood A. The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000research. 7: 326. PMID 29560266 DOI: 10.12688/F1000Research.11771.1 |
0.364 |
|
| 2018 |
Liu Q, Lu C, Dai W, Li K, Xu J, Huang Y, Li G, Kang Y, Sood AK, Xu C. Association of biobehavioral factors with non-coding RNAs in cervical cancer. Bioscience Trends. 12: 24-31. PMID 29553098 DOI: 10.5582/Bst.2017.01325 |
0.36 |
|
| 2018 |
Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Frontiers in Oncology. 8: 9. PMID 29456965 DOI: 10.3389/Fonc.2018.00009 |
0.37 |
|
| 2018 |
Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, ... ... Sood AK, et al. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nature Communications. 9: 476. PMID 29396402 DOI: 10.1038/S41467-017-02811-7 |
0.424 |
|
| 2018 |
Velazquez-Torres G, Shoshan E, Ivan C, Huang L, Fuentes-Mattei E, Paret H, Kim SJ, Rodriguez-Aguayo C, Xie V, Brooks D, Jones SJM, Robertson AG, Calin G, Lopez-Berenstein G, Sood A, et al. A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nature Communications. 9: 461. PMID 29386624 DOI: 10.1038/S41467-018-02851-7 |
0.303 |
|
| 2018 |
Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley KM, Sood AK, Isidoro C, Mukherjee P, Song YS, Dhanasekaran DN. Lysophosphatidic Acid Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Research. PMID 29386184 DOI: 10.1158/0008-5472.Can-17-1624 |
0.515 |
|
| 2018 |
Dood R, Zhou Y, Armbruster SD, Tworoger S, Coleman RL, Sood A, Baggerly KA. Defining survivorship and surveillance with evidence. Journal of Clinical Oncology. 36: 6528-6528. DOI: 10.1200/Jco.2018.36.15_Suppl.6528 |
0.351 |
|
| 2018 |
Westin SN, Litton JK, Williams RA, Shepherd CJ, Brugger W, Pease EJ, Soliman PT, Frumovitz MM, Levenback CF, Sood A, Meyer L, Moulder SL, Valero V, Saleem S, Rodriguez AM, et al. Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer. Journal of Clinical Oncology. 36: 5504-5504. DOI: 10.1200/Jco.2018.36.15_Suppl.5504 |
0.319 |
|
| 2018 |
Cho MS, Gonzalez-Pagan O, Pinto KC, Sood A, Afshar-Kharghan V. The Inhibition of Platelets Restore Anti-Tumor Immune Response to Ovarian Cancer and Its Therapeutic Implication Blood. 132: 3698-3698. DOI: 10.1182/Blood-2018-99-116530 |
0.445 |
|
| 2018 |
Lara OD, Rodriquez-Aguayo C, Bayrakter E, Amero P, Mangala S, LaFargue C, Tari-Ashizawa A, Lopez-Berestein G, Sood A. Abstract 5786: Grabbing GRB2: The use of liposome-incorporated Grb2 antisense oligonucleotides as a novel therapy in gynecologic malignancies Cancer Research. 78: 5786-5786. DOI: 10.1158/1538-7445.Am2018-5786 |
0.425 |
|
| 2018 |
Ma S, Pradeep S, Wu S, Kim MS, Hu W, Mangala S, Coleman RL, Sood AK. Abstract 4817: EP-100 sensitizes BRCA wild-type ovarian cancer cells to PARP inhibitor Cancer Research. 78: 4817-4817. DOI: 10.1158/1538-7445.Am2018-4817 |
0.482 |
|
| 2018 |
Huang T, Sood AK, Tworoger SS. Abstract 4252: Antihypertensive medication use and ovarian cancer survival Epidemiology. DOI: 10.1158/1538-7445.Am2018-4252 |
0.386 |
|
| 2018 |
Amero P, Rodriguez-Aguayo C, Lokesh G, Bayraktar E, Ivan C, Chaudhari R, Zhang S, Volk D, Sood A, Lopez-Berestein G. Development of novel modified aptamers to target Axl receptor in ovarian cancer Annals of Oncology. 29: iii17. DOI: 10.1093/Annonc/Mdy047.029 |
0.427 |
|
| 2018 |
Molin GZD, Fleming ND, Fellman B, Dood RL, Lara OD, LaFargue CJ, Coleman RL, Soliman PT, Schmeler KM, Westin SN, Sood AK. Venous thromboembolism (VTE) in ovarian cancer during neoadjuvant chemotherapy: Is it time to start prophylaxis? Gynecologic Oncology. 149: 155. DOI: 10.1016/J.Ygyno.2018.04.354 |
0.447 |
|
| 2018 |
LaFargue CJ, Fleming ND, Fellman B, Dood RL, Lara OD, Molin GZD, Westin SN, Coleman RL, Sood AK. From unresectable to cancer-free at interval surgery: An evaluation of complete pathologic responders Gynecologic Oncology. 149: 87. DOI: 10.1016/J.Ygyno.2018.04.199 |
0.371 |
|
| 2018 |
Lara OD, Rodriguez-Aguayo C, Bayraktar E, Amero P, Mangala S, LaFargue CJ, Sood AK. Grabbing the Grb2/GAB2 complex in ovarian cancer Gynecologic Oncology. 149: 60. DOI: 10.1016/J.Ygyno.2018.04.133 |
0.433 |
|
| 2018 |
Hansen JM, Sood AK, Coleman RL, Westin SN, Ramirez PT, Fellman B, Soliman PT, Schmeler KM, Fleming ND. Concordance of laparoscopy in predicting intraperitoneal spread and residual disease at tumor reductive surgery in advanced ovarian cancer Gynecologic Oncology. 149: 622. DOI: 10.1016/J.Ygyno.2018.03.016 |
0.427 |
|
| 2017 |
McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, ... ... Sood A, et al. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. Journal of the National Cancer Institute. PMID 29267866 DOI: 10.1093/Jnci/Djx257 |
0.46 |
|
| 2017 |
Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. The Journal of Clinical Investigation. PMID 29251630 DOI: 10.1172/Jci95200 |
0.526 |
|
| 2017 |
Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, ... ... Sood AK, et al. HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports. PMID 29249663 DOI: 10.1016/J.Stemcr.2017.11.010 |
0.442 |
|
| 2017 |
Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, ... Sood AK, et al. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Molecular Therapy. Nucleic Acids. 9: 251-262. PMID 29246304 DOI: 10.1016/J.Omtn.2017.06.023 |
0.528 |
|
| 2017 |
Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Reviews. PMID 29243000 DOI: 10.1007/S10555-017-9717-6 |
0.325 |
|
| 2017 |
Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, et al. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. Jama Oncology. PMID 29242937 DOI: 10.1001/Jamaoncol.2017.4218 |
0.411 |
|
| 2017 |
Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs R, ... Sood AK, et al. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Molecular Cancer Therapeutics. PMID 29237804 DOI: 10.1158/1535-7163.Mct-17-0006 |
0.49 |
|
| 2017 |
Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, ... ... Sood AK, et al. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 8: 96496-96505. PMID 29228548 DOI: 10.18632/Oncotarget.20410 |
0.356 |
|
| 2017 |
Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, ... ... Sood AK, et al. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Reports. 21: 2785-2795. PMID 29212026 DOI: 10.1016/J.Celrep.2017.11.020 |
0.393 |
|
| 2017 |
Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Demarzo A, Sood AK, Zhang L, Dang CV. MYC targeted long non-coding RNA DANCR promotes cancer in part by reducing p21 levels. Cancer Research. PMID 29180471 DOI: 10.1158/0008-5472.Can-17-0815 |
0.487 |
|
| 2017 |
Yasukawa M, Liu Y, Hu L, Cogdell D, Gharpure KM, Pradeep S, Nagaraja AS, Sood AK, Zhang W. ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy. Oncotarget. 8: 88410-88420. PMID 29179445 DOI: 10.18632/Oncotarget.11120 |
0.489 |
|
| 2017 |
Takiuchi T, Blake EA, Matsuo K, Sood AK, Brasky TM. Aspirin use and endometrial cancer risk and survival. Gynecologic Oncology. PMID 29132875 DOI: 10.1016/J.Ygyno.2017.10.026 |
0.461 |
|
| 2017 |
Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, ... ... Sood AK, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. The Journal of Clinical Investigation. PMID 29130936 DOI: 10.1172/Jci91553 |
0.386 |
|
| 2017 |
Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, Cole SW. Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. Cancer. PMID 29112229 DOI: 10.1002/Cncr.31078 |
0.414 |
|
| 2017 |
Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, ... ... Sood AK, et al. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene. PMID 29059175 DOI: 10.1038/Onc.2017.348 |
0.354 |
|
| 2017 |
Hu X, Sood AK, Dang CV, Zhang L. The role of long noncoding RNAs in cancer: the dark matter matters. Current Opinion in Genetics & Development. 48: 8-15. PMID 29054012 DOI: 10.1016/J.Gde.2017.10.004 |
0.431 |
|
| 2017 |
Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang W. Erratum to: MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. Journal of Hematology & Oncology. 10: 163. PMID 28985752 DOI: 10.1186/S13045-017-0525-9 |
0.445 |
|
| 2017 |
Chung JF, Lee SJ, Sood AK. Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment. Oncotarget. 8: 69047-69061. PMID 28978180 DOI: 10.18632/Oncotarget.17749 |
0.351 |
|
| 2017 |
Pu T, Xiong L, Liu Q, Zhang M, Cai Q, Liu H, Sood AK, Li G, Kang Y, Xu C. Delineation of retroperitoneal metastatic lymph nodes in ovarian cancer with near-infrared fluorescence imaging. Oncology Letters. 14: 2869-2877. PMID 28928826 DOI: 10.3892/Ol.2017.6521 |
0.343 |
|
| 2017 |
Sood AK, Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu S, Mangala LS, et al. Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28855350 DOI: 10.1158/1078-0432.Ccr-17-0647 |
0.635 |
|
| 2017 |
Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, ... ... Sood AK, et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nature Communications. 8: 310. PMID 28827520 DOI: 10.1038/S41467-017-00411-Z |
0.446 |
|
| 2017 |
Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, ... ... Sood AK, et al. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. Jci Insight. 2. PMID 28814667 DOI: 10.1172/Jci.Insight.93076 |
0.728 |
|
| 2017 |
Fleming ND, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell MF, Sood AK. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecologic Oncology. PMID 28774461 DOI: 10.1016/J.Ygyno.2017.07.137 |
0.406 |
|
| 2017 |
Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Reviews. PMID 28730545 DOI: 10.1007/S10555-017-9682-0 |
0.368 |
|
| 2017 |
Cuneo MG, Schrepf A, Slavich GM, Thaker PH, Goodheart M, Bender D, Cole SW, Sood AK, Lutgendorf SK. Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer. Psychoneuroendocrinology. 84: 139-142. PMID 28711723 DOI: 10.1016/J.Psyneuen.2017.06.019 |
0.419 |
|
| 2017 |
Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, ... Sood AK, et al. PRKCI promotes immune suppression in ovarian cancer. Genes & Development. PMID 28698296 DOI: 10.1101/Gad.296640.117 |
0.5 |
|
| 2017 |
Cho MS, Noh K, Haemmerle M, Li D, Park H, Hu Q, Hisamatsu T, Mitamura T, Mak SLC, Kunapuli S, Ma Q, Sood AK, Afshar-Kharghan V. Role of ADP receptors on platelets in the growth of ovarian cancer. Blood. PMID 28679740 DOI: 10.1182/Blood-2017-02-769893 |
0.477 |
|
| 2017 |
Li L, Zheng H, Huang Y, Huang C, Zhang S, Tian J, Li P, Sood AK, Zhang W, Chen K. DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer. Carcinogenesis. PMID 28637314 DOI: 10.1093/Carcin/Bgx057 |
0.368 |
|
| 2017 |
Tseng JH, Bisogna M, Hoang LN, Olvera N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Levine DA, Jelinic P. miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. Scientific Reports. 7: 3614. PMID 28620240 DOI: 10.1038/S41598-017-03972-7 |
0.308 |
|
| 2017 |
Hu Q, Hisamatsu T, Hammerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong ST, Sood AK, Afshar-Kharghan V. Role of platelet-derived Tgfβ1 in the progression of ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28611202 DOI: 10.1158/1078-0432.Ccr-16-3272 |
0.49 |
|
| 2017 |
Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew W, Lester J, Moore KM, Karlan BY, Levine DA, ... Sood AK, et al. Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. Gynecologic Oncology. PMID 28527672 DOI: 10.1016/J.Ygyno.2017.05.008 |
0.348 |
|
| 2017 |
Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Zarfati G, Trakhtenbrot L, Levy-Barda A, Jiang D, Rodriguez-Aguayo C, Pradeep S, van Praag Y, Lopez-Berestein G, David A, ... ... Sood AK, et al. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. Oncotarget. 27380-27392. PMID 28423708 DOI: 10.18632/Oncotarget.16068 |
0.428 |
|
| 2017 |
Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, Denizli M, Mitra R, Ozpolat B, Calin GA, Sood AK, et al. Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget. 8: 20145-20164. PMID 28423620 DOI: 10.18632/Oncotarget.15525 |
0.367 |
|
| 2017 |
Sans M, Gharpure KM, Tibshirani R, Zhang J, Liang L, Liu J, Young JH, Dood R, Sood AK, Eberlin L. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Research. PMID 28416487 DOI: 10.1158/0008-5472.Can-16-3044 |
0.398 |
|
| 2017 |
Wang Y, Xu X, Yu S, Kang KJ, Zhou Z, Han L, Tsang YH, Li J, Chen H, Mangala LS, Yuan Y, Eterovic AK, Lu Y, Sood AK, Scott KL, et al. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Research. PMID 28411194 DOI: 10.1101/Gr.219741.116 |
0.377 |
|
| 2017 |
Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, ... ... Sood AK, et al. Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 8: 17406. PMID 28403581 DOI: 10.18632/Oncotarget.15921 |
0.38 |
|
| 2017 |
Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, ... ... Sood AK, et al. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. Journal of the National Cancer Institute. 109. PMID 28376174 DOI: 10.1093/Jnci/Djw296 |
0.686 |
|
| 2017 |
Trudel-Fitzgerald C, Poole EM, Idahl A, Lundin E, Sood AK, Kawachi I, Kubzansky LD, Tworoger SS. The Association of Work Characteristics With Ovarian Cancer Risk and Mortality. Psychosomatic Medicine. PMID 28306624 DOI: 10.1097/Psy.0000000000000464 |
0.404 |
|
| 2017 |
Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodriguez-Aguayo C, Lopez-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M. HSP70 inhibition synergistically enhances the effects of magnetic fluid hyperthermia in ovarian cancer. Molecular Cancer Therapeutics. PMID 28223424 DOI: 10.1158/1535-7163.Mct-16-0519 |
0.47 |
|
| 2017 |
Matsuo K, Machida H, Takiuchi T, Grubbs BH, Roman LD, Sood AK, Gershenson DM. Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. Gynecologic Oncology. PMID 28131526 DOI: 10.1016/J.Ygyno.2017.01.019 |
0.344 |
|
| 2017 |
Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, ... Sood AK, et al. Metastasis regulation by PPARD expression in cancer cells. Jci Insight. 2: e91419. PMID 28097239 DOI: 10.1172/Jci.Insight.91419 |
0.502 |
|
| 2017 |
Naing A, Lopez-Berestein G, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Sulovic S, Meng X, Jazaeri AA, Ng CS, Karp DD, Subbiah V, Meric-Bernstam F, ... ... Sood A, et al. EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial. Journal of Clinical Oncology. 35: TPS2604-TPS2604. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps2604 |
0.456 |
|
| 2017 |
Dood R, Fleming ND, Coleman RL, Westin SN, Sood A. When advanced ovarian cancer is not ovarian cancer. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E17066 |
0.457 |
|
| 2017 |
Ghazaly EA, Quesne JL, Jiang D, Mangala SL, Chettle J, Rodriguez-Aguayo C, Lopez-Berestein G, Gnanaranjan C, Mura M, Stavraka C, Sood AK, Blagden SP. Abstract B30: The RNA-binding protein LARP1 is a cancer therapeutic target Cancer Research. 77. DOI: 10.1158/1538-7445.Transcontrol16-B30 |
0.478 |
|
| 2017 |
Zuo X, Xu W, Xu M, Tian R, Moussalli MJMJ, Mao F, Gagea M, Wei D, Sood AK, Shureiqi I. Abstract 844: PPARD downregulation in cancer cells suppresses metastases by inhibiting tumor angiogenesis and EMT Cancer Research. 77: 844-844. DOI: 10.1158/1538-7445.Am2017-844 |
0.5 |
|
| 2017 |
Lyons YA, Pradeep S, Hansen JM, Wagner MJ, Dood RL, Wu SY, Previs RA, Hu W, Coleman RL, Sood AK. Abstract 788: Less is more: macrophage depletion via CSF1/CSF1R pathway improves anti-VEGF therapy after adaptive resistance Cancer Research. 77: 788-788. DOI: 10.1158/1538-7445.Am2017-788 |
0.392 |
|
| 2017 |
Kheder E, Huang HJ, Wu A, Hong DS, Piha-Paul SA, Karp DD, Fu S, Subbiah V, Tsimberidou AM, Naing A, Diab A, Javle M, Kopetz S, Sood AK, Kurie JM, et al. Abstract 642: Detection of circulating antibodies against KRAS in patients with advanced cancers Immunology. 77: 642-642. DOI: 10.1158/1538-7445.Am2017-642 |
0.372 |
|
| 2017 |
McGuire MH, Herbrich S, Wu S, Wang Y, Rupaimoole R, Yao H, Gharpure K, Lopez-Berestein G, Baggerly K, Sood A. Abstract 5377: Intragenic DNA methylation and increased gene expression: New directions from pan-cancer analysis Cancer Research. 77: 5377-5377. DOI: 10.1158/1538-7445.Am2017-5377 |
0.354 |
|
| 2017 |
Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Noh K, Filant J, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Bartholomeusz GA, ... ... Sood AK, et al. Abstract 473: PRKRA/PACT expression promotes chemoresistance in mucinous ovarian cancer Cancer Research. 77: 473-473. DOI: 10.1158/1538-7445.Am2017-473 |
0.457 |
|
| 2017 |
Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Dorniak PL, ... Sood AK, et al. Abstract 4144: Role of CTGF in hyperthermia resistance in ovarian and uterine cancers Cancer Research. 77: 4144-4144. DOI: 10.1158/1538-7445.Am2017-4144 |
0.522 |
|
| 2017 |
Yang H, Zhang S, Mao W, Ahmed AA, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Le X, Lu Z, Bast RC. Abstract 3564: Silencing pfkfb2 enhances paclitaxel sensitivity by modulating metabolism of p53 wt ovarian and breast cancer cells and xenografts Cancer Research. 77: 3564-3564. DOI: 10.1158/1538-7445.Am2017-3564 |
0.4 |
|
| 2017 |
Kanlikilicer P, Bayraktar R, Rashed M, Aslan B, Calin GA, Sood AK, Lopez-Berestein G. Abstract 1988: Exosome-mediated ovarian cancer tumorigenesis mediated by miR1246/Rb/Cav1 axis Cancer Research. 77: 1988-1988. DOI: 10.1158/1538-7445.Am2017-1988 |
0.378 |
|
| 2017 |
Villar-Prados A, Wu SY, Roszik J, Sood AK, Engelhardt MI. Abstract 1528: Forecasting novel therapies by understanding the role BRD4 in regulating the Notch3 signaling in ovarian cancer Cancer Research. 77: 1528-1528. DOI: 10.1158/1538-7445.Am2017-1528 |
0.415 |
|
| 2017 |
Ramondetta L, Thaker P, Hu W, Urbauer D, Chisholm G, Sood A. Beta Adrenergic Blockade Is Feasible During Primary Treatment for Ovarian Cancer [10J] Obstetrics & Gynecology. 129. DOI: 10.1097/01.Aog.0000514985.46810.B0 |
0.379 |
|
| 2017 |
Taylor J, Westin S, Sharafi S, Jazaeri A, Frumovitz M, Soliman P, Sood A, Lu K, Savelieva K, Mills G, Vergara-Silva A, Coleman R. 992TiPN-DUR: Matched pair pharmacodynamics study of neoadjuvant durvalumab in combination with chemotherapy in frontline ovarian cancer Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx372.063 |
0.456 |
|
| 2017 |
Westin S, Litton J, Williams R, Soliman P, Frumovitz M, Schmeler K, Jazaeri A, Sood A, Lu K, Moulder S, Murthy R, Rodriguez A, Samuel C, Engerman L, Cyriac A, et al. 391PPhase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx367.025 |
0.383 |
|
| 2017 |
Fleming N, Coleman R, Westin S, Sood A. When Advanced Ovarian Cancer is not Ovarian Cancer: Characteristics and Predictors of non-Ovarian Pathology in a Systematic, Laparoscopic-Based System Gynecologic Oncology. 147: 233. DOI: 10.1016/J.Ygyno.2017.07.110 |
0.471 |
|
| 2017 |
Bottsford-Miller JN, Haemmerle M, Wagner MJ, Lyons YA, Previs RA, Hansen JM, Dood RL, Hu W, Lichtenberger LM, Sood AK. Aspirin-PC is a novel, safe and efficacious compound in ovarian cancer Gynecologic Oncology. 145: 85-86. DOI: 10.1016/J.Ygyno.2017.03.200 |
0.403 |
|
| 2017 |
Hu W, Ivan C, Lyons YA, Hansen JM, Dood RL, Wagner MJ, Previs RA, Frumovitz M, Coleman RL, Sood AK. Dll3 alterations predict poor survival in gynecological cancers Gynecologic Oncology. 145: 78. DOI: 10.1016/J.Ygyno.2017.03.185 |
0.402 |
|
| 2017 |
Ramondetta LM, Hu W, Thaker PH, Urbauer D, Westin SN, Nagaraja AS, Ramirez PT, Fleming ND, Sahai S, Nick AM, Sood AK. No need to stress: Prospective clinical trial of adrenergic blockade during primary treatment in women with epithelial ovarian cancer Gynecologic Oncology. 145: 33-34. DOI: 10.1016/J.Ygyno.2017.03.088 |
0.381 |
|
| 2017 |
Thaker PH, Kuroki LM, Hu W, Zighelboim I, Ramondetta LM, Hagemann AR, Massad LS, Powell MA, Mutch DG, Sood AK. Overcoming stress effects: A prospective feasibility trial of beta-blockers with upfront ovarian cancer therapy Gynecologic Oncology. 145: 18. DOI: 10.1016/J.Ygyno.2017.03.058 |
0.374 |
|
| 2017 |
Dood RL, Nagaraja AS, Lyons YA, Hansen JM, Previs RA, Jackson DB, Coleman RL, Sood AK. Knocking out stress: A systems-based identification of optimal drug combinations to improve ovarian cancer outcomes Gynecologic Oncology. 145: 15. DOI: 10.1016/J.Ygyno.2017.03.053 |
0.356 |
|
| 2017 |
Previs R, Moss T, Zand B, Hansen J, Dood R, Armaiz-Pena G, Lyons Y, Coleman R, Sood A. Pretty fly for GPI: Altered carbohydrate metabolism in ovarian cancer Gynecologic Oncology. 145: 13. DOI: 10.1016/J.Ygyno.2017.03.047 |
0.669 |
|
| 2017 |
Armer JS, Schrepf A, Cuneo MG, Christensen D, Thaker PH, Slavich GM, Goodheart MJ, Cole SW, Sood AK, Lutgendorf SK. Anxiety levels parallel changes in inflammation over time in ovarian cancer patients Brain Behavior and Immunity. 66. DOI: 10.1016/J.Bbi.2017.07.104 |
0.385 |
|
| 2016 |
Ravoori MK, Singh S, Bhavane R, Sood AK, Anvari B, Bankson J, Annapragada A, Kundra V. Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent. Scientific Reports. 6: 38991. PMID 28004770 DOI: 10.1038/Srep38991 |
0.4 |
|
| 2016 |
Han HD, Byeon Y, Jang JH, Jeon HN, Kim GH, Kim MG, Pack CG, Kang TH, Jung ID, Lim YT, Lee YJ, Lee JW, Shin BC, Ahn HJ, Sood AK, et al. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Scientific Reports. 6: 38348. PMID 27910914 DOI: 10.1038/Srep38348 |
0.316 |
|
| 2016 |
Arun B, Austin T, Babiera GV, Basen-Engquist K, Carmack CL, Chaoul A, Cohen L, Connelly L, Haddad R, Harrison C, Li Y, Mallaiah S, Nagarathna R, Parker PA, Perkins GH, ... ... Sood A, et al. A Comprehensive Lifestyle Randomized Clinical Trial: Design and Initial Patient Experience. Integrative Cancer Therapies. PMID 27903842 DOI: 10.1177/1534735416679516 |
0.309 |
|
| 2016 |
Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis R, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, ... ... Sood AK, et al. Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27903673 DOI: 10.1158/1078-0432.Ccr-16-1025 |
0.328 |
|
| 2016 |
Pi F, Zhang H, Li H, Thiviyanathan V, Gorenstein DG, Sood AK, Guo P. RNA Nanoparticles Harboring Annexin A2 Aptamer Can Target Ovarian Cancer for Tumor-Specific Doxorubicin Delivery. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 27890659 DOI: 10.1016/J.Nano.2016.11.015 |
0.377 |
|
| 2016 |
Wang H, Li X, Volk DE, Lokesh GL, Elizondo-Riojas MA, Li L, Nick AM, Sood AK, Rosenblatt KP, Gorenstein DG. Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery. Biotechniques. 61: 249-259. PMID 27839510 DOI: 10.2144/000114473 |
0.319 |
|
| 2016 |
Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, ... ... Sood AK, et al. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metabolism. 24: 685-700. PMID 27829138 DOI: 10.1016/J.Cmet.2016.10.011 |
0.495 |
|
| 2016 |
Previs RA, Sood AK, Mills GB, Westin SN. The rise of genomic profiling in ovarian cancer. Expert Review of Molecular Diagnostics. PMID 27828713 DOI: 10.1080/14737159.2016.1259069 |
0.458 |
|
| 2016 |
Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, ... ... Sood AK, et al. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Reports. 17: 1621-1631. PMID 27806300 DOI: 10.1016/J.Celrep.2016.10.020 |
0.474 |
|
| 2016 |
Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, ... Sood AK, et al. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Research. 76: 6320-6330. PMID 27803105 DOI: 10.1158/0008-5472.Can-16-0854 |
0.485 |
|
| 2016 |
Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GL, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, ... ... Sood AK, et al. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. Jci Insight. 1: e87754. PMID 27777972 DOI: 10.1172/Jci.Insight.87754 |
0.421 |
|
| 2016 |
Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang W. MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. Journal of Hematology & Oncology. 9: 112. PMID 27760566 DOI: 10.1186/S13045-016-0342-6 |
0.413 |
|
| 2016 |
Kanlikilicer P, Saber M, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, et al. Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Research. PMID 27742688 DOI: 10.1158/0008-5472.Can-16-0714 |
0.447 |
|
| 2016 |
Sun Y, Ji P, Chen T, Zhou X, Yang D, Guo Y, Liu Y, Hu L, Xia D, Liu Y, Multani AS, Shmulevich I, Kucherlapati R, Kopetz S, Sood AK, et al. MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. The Journal of Pathology. PMID 27741356 DOI: 10.1002/Path.4823 |
0.372 |
|
| 2016 |
Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. microRNA Therapeutics in Cancer - An Emerging Concept. Ebiomedicine. PMID 27720213 DOI: 10.1016/J.Ebiom.2016.09.017 |
0.349 |
|
| 2016 |
Grossberg A, Vichaya E, Christian D, Molkentine J, Vermeer DW, Heijnen C, Kavelaars A, Lee JH, Sood AK, Dantzer R. The Role of Neuroinflammation in Tumor-Induced Fatigue. International Journal of Radiation Oncology, Biology, Physics. 96: E562. PMID 27675023 DOI: 10.1016/J.Ijrobp.2016.06.2035 |
0.327 |
|
| 2016 |
Huang Y, Lichtenberger LM, Taylor M, Bottsford-Miller JN, Haemmerle M, Wagner MJ, Lyons Y, Pradeep S, Hu W, Previs RA, Hansen JM, Fang D, Domiak PL, Filant J, Dial EJ, ... Sood AK, et al. Anti-tumor and Anti-angiogenic Effects of Aspirin-PC in Ovarian Cancer. Molecular Cancer Therapeutics. PMID 27638860 DOI: 10.1158/1535-7163.Mct-16-0074 |
0.501 |
|
| 2016 |
Barata P, Sood AK, Hong DS. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treatment Reviews. 50: 35-47. PMID 27612280 DOI: 10.1016/J.Ctrv.2016.08.004 |
0.383 |
|
| 2016 |
Huang T, Tworoger SS, Hecht JL, Rice MS, Sood AK, Kubzansky LD, Poole EM. Association of ovarian tumor β2-adrenergic receptor status with ovarian cancer risk factors and survival. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27587791 DOI: 10.1158/1055-9965.Epi-16-0534 |
0.478 |
|
| 2016 |
Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nature Reviews. Disease Primers. 2: 16061. PMID 27558151 DOI: 10.1038/nrdp.2016.61 |
0.386 |
|
| 2016 |
Key NS, Khorana AA, Mackman N, McCarty OJ, White GC, Francis CW, McCrae KR, Palumbo JS, Raskob GE, Chan AT, Sood AK. Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Research. 76: 3671-3675. PMID 27527638 DOI: 10.1158/0008-5472.Can-15-3100 |
0.43 |
|
| 2016 |
Yasukawa M, Liu Y, Hu L, Cogdell D, Gharpure KM, Pradeep S, Nagaraja AS, Sood AK, Zhang W. ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy. Oncotarget. PMID 27517494 DOI: 10.18632/oncotarget.11120 |
0.388 |
|
| 2016 |
Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, ... ... Sood AK, et al. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell. PMID 27478041 DOI: 10.1016/J.Ccell.2016.06.020 |
0.481 |
|
| 2016 |
Hu Q, Wang M, Cho MS, Wang C, Nick AM, Thiagarajan P, Aung FM, Han X, Sood AK, Afshar-Kharghan V. Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. Bba Clinical. 6: 76-81. PMID 27453821 DOI: 10.1016/J.Bbacli.2016.06.003 |
0.331 |
|
| 2016 |
Srivastava A, Babu A, Filant J, Moxley KM, Ruskin R, Dhanasekaran D, Sood AK, McMeekin S, Ramesh R. Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer. Journal of Biomedical Nanotechnology. 12: 1159-73. PMID 27319211 DOI: 10.1166/Jbn.2016.2205 |
0.413 |
|
| 2016 |
Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, et al. ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell. 29: 874-888. PMID 27300436 DOI: 10.1016/J.Ccell.2016.04.016 |
0.387 |
|
| 2016 |
Matsuo K, Cahoon SS, Yoshihara K, Shida M, Kakuda M, Adachi S, Moeini A, Machida H, Garcia-Sayre J, Ueda Y, Enomoto T, Mikami M, Roman LD, Sood AK. Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer. Obstetrics and Gynecology. PMID 27275802 DOI: 10.1097/Aog.0000000000001491 |
0.333 |
|
| 2016 |
Feng S, Kroll MH, Nick AM, Sood AK, Afshar-Kharghan V. Platelets are not hyperreactive in patients with ovarian cancer. Platelets. 1-3. PMID 27185008 DOI: 10.3109/09537104.2016.1174204 |
0.421 |
|
| 2016 |
Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, et al. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Reports. PMID 27160903 DOI: 10.1016/J.Celrep.2016.04.034 |
0.484 |
|
| 2016 |
Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, et al. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. PMID 27147567 DOI: 10.18632/Oncotarget.9048 |
0.418 |
|
| 2016 |
Christensen DK, Armaiz-Pena GN, Ramirez E, Matsuo K, Zimmerman B, Zand B, Shinn E, Goodheart MJ, Bender D, Thaker PH, Ahmed A, Penedo FJ, DeGeest K, Mendez L, Domann F, ... Sood AK, et al. SSRI use and clinical outcomes in epithelial ovarian cancer. Oncotarget. PMID 27121207 DOI: 10.18632/Oncotarget.8891 |
0.696 |
|
| 2016 |
Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncology (London, England). PMID 27087632 DOI: 10.2217/Fon-2016-0002 |
0.371 |
|
| 2016 |
Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, ... ... Sood AK, et al. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. The Journal of Clinical Investigation. PMID 27064283 DOI: 10.1172/Jci85086 |
0.706 |
|
| 2016 |
Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, ... ... Sood AK, et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications. 7: 11169. PMID 27041221 DOI: 10.1038/Ncomms11169 |
0.622 |
|
| 2016 |
Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, ... ... Sood AK, et al. miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. PMID 27036018 DOI: 10.18632/Oncotarget.8412 |
0.404 |
|
| 2016 |
Poole EM, Kubzansky LD, Sood AK, Okereke OI, Tworoger SS. A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. Cancer Causes & Control : Ccc. 27: 661-8. PMID 27023470 DOI: 10.1007/S10552-016-0739-0 |
0.481 |
|
| 2016 |
Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, Yang D. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecologic Oncology. 141: 57-64. PMID 27016230 DOI: 10.1016/J.Ygyno.2016.01.004 |
0.42 |
|
| 2016 |
Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, ... ... Sood AK, et al. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Molecular Cancer Therapeutics. PMID 27009216 DOI: 10.1158/1535-7163.Mct-15-0144 |
0.522 |
|
| 2016 |
Rytelewski M, Vareki SM, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. PMID 26959114 DOI: 10.18632/Oncotarget.7883 |
0.447 |
|
| 2016 |
Chung JF, Lee SJ, Sood AK. Immunological and pleiotropic effects of individual β-blockers and their relevance in cancer therapies. Expert Opinion On Investigational Drugs. PMID 26954371 DOI: 10.1517/13543784.2016.1164141 |
0.354 |
|
| 2016 |
Di Guilmi J, Salvo G, Mehran R, Sood AK, Coleman RL, Lu KH, Vaporciyan A, Ramirez PT. Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 26937753 DOI: 10.1097/Igc.0000000000000680 |
0.349 |
|
| 2016 |
Huang T, Poole EM, Eliassen AH, Okereke OI, Kubzansky LD, Sood AK, Forman JP, Tworoger SS. Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. International Journal of Cancer. PMID 26934358 DOI: 10.1002/Ijc.30066 |
0.326 |
|
| 2016 |
Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. PMID 26918603 DOI: 10.18632/Oncotarget.7618 |
0.301 |
|
| 2016 |
Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discovery. 6: 235-46. PMID 26865249 DOI: 10.1158/2159-8290.Cd-15-0893 |
0.394 |
|
| 2016 |
Han HD, Cho YJ, Cho SK, Byeon Y, Jeon HN, Kim HS, Kim BG, Bae DS, Lopez-Berestein G, Sood AK, Shin BC, Park YM, Lee JW. Linalool-incorporated nanoparticles as a novel anticancer agent for epithelial ovarian carcinoma. Molecular Cancer Therapeutics. PMID 26861249 DOI: 10.1158/1535-7163.Mct-15-0733-T |
0.36 |
|
| 2016 |
Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer. European Journal of Cancer (Oxford, England : 1990). 56: 131-43. PMID 26849037 DOI: 10.1016/J.Ejca.2015.12.016 |
0.501 |
|
| 2016 |
Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, ... ... Sood AK, et al. Role of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute. 108. PMID 26819345 DOI: 10.1093/Jnci/Djv426 |
0.675 |
|
| 2016 |
Mitamura T, Gourley C, Sood AK. Prediction of anti-angiogenesis escape. Gynecologic Oncology. 141: 80-5. PMID 26748214 DOI: 10.1016/J.Ygyno.2015.12.033 |
0.372 |
|
| 2016 |
Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, ... ... Sood AK, et al. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. PMID 26725326 DOI: 10.1038/Onc.2015.492 |
0.66 |
|
| 2016 |
Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods in Molecular Biology (Clifton, N.J.). 1402: 189-97. PMID 26721492 DOI: 10.1007/978-1-4939-3378-5_15 |
0.401 |
|
| 2016 |
Zhang X, Lopez-Berestein G, Sood AK, Calin GA. Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. Methods in Molecular Biology (Clifton, N.J.). 1402: 33-41. PMID 26721482 DOI: 10.1007/978-1-4939-3378-5_5 |
0.308 |
|
| 2016 |
Westin SN, Galbraith SM, Godin R, O'Connor MJ, Munsell MF, Savelieva K, Nick AM, Soliman PT, Sood A, Mills GB, Coleman RL. WEE WIN: Window of opportunity study of induction WEE1 inhibition in advanced high-grade serous ovarian cancer. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps5610 |
0.431 |
|
| 2016 |
Nick AM, Copper G, Wu W, Dantone C, Haider A, Fellman B, Davis DW, Sood A. Characterization of CTCs isolated from patients with recurrent ovarian cancer using an antibody-free CTC isolation device. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E17056 |
0.439 |
|
| 2016 |
Hansen JM, Ring KL, Baggerly KA, Wu S, Timms K, Neff C, Hughes E, Previs RA, Broaddus R, Coleman RL, Lu KH, Sood A. Clinical significance of homologous recombination deficiency (HRD) score testing in endometrial cancer patients. Journal of Clinical Oncology. 34: 5584-5584. DOI: 10.1200/Jco.2016.34.15_Suppl.5584 |
0.45 |
|
| 2016 |
Liang L, Mercado-Uribe I, Niu N, Jiang Y, Cheng W, Broaddus R, Bast R, Mills G, Sood AK, Liu J. Abstract B22: Establishment of Patient-Derived Xenograft (PDX) Models of Ovarian Cancer Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B22 |
0.456 |
|
| 2016 |
Pradeep S, Huang J, Mora E, Wu SY, Li C, Lopez-Berestein G, Jackson D, Sood A. Abstract B68: Erythropoietin stimulates ovarian tumor growth via EphB4. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B68 |
0.47 |
|
| 2016 |
Shoshan E, Huang L, Vasquez ME, Lee H, Kim S, Ivan C, Calin GA, Sood AK, Hwu P, Gershenwald JE, Markel G, Fidler IJ, Bar-Eli M. Abstract PR05: Control of the melanoma metastatic phenotype by A-to-I microRNA editing Cancer Research. 76. DOI: 10.1158/1538-7445.Tme16-Pr05 |
0.331 |
|
| 2016 |
Rashed MH, Kanlikilicer P, Aguayo CR, Kabil NN, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Mitra R, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Berestein GL. Abstract LB-169: Ovarian cancer cells selectively release exosomes containing tumor suppressor miRNAs to maintain SRC-mediated oncogenic activities Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-169 |
0.42 |
|
| 2016 |
Niu N, Zhang J, Zhang N, Mercado-Uribe I, Tao F, Han Z, Pathak S, Multani A, Kuang J, Yao J, Bast R, Sood A, Hung M, Liu J. Abstract LB-119: Single-cell live imaging of paclitaxel-resistant cancer cell generation Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-119 |
0.45 |
|
| 2016 |
Kanlikilicer P, Rashed MMHS, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Cristian R, Bayraktar E, Picher M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Abstract 763: Exosomal miR-6126 as a novel tumor suppressor in ovarian cancer Cancer Research. 76: 763-763. DOI: 10.1158/1538-7445.Am2016-763 |
0.472 |
|
| 2016 |
Lyons YA, Pradeep S, Hansen JM, Previs RA, Yao H, Baggerly KA, Sood AK. Abstract 723: Distinguishing macrophages by a unique gene signature to measure response to treatment Cancer Research. 76: 723-723. DOI: 10.1158/1538-7445.Am2016-723 |
0.378 |
|
| 2016 |
Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi H, Stone RL, Cho MS, Nick AM, Lopez-Berestein G, Afshar-Khargan V, Sood AK. Abstract 5048: Platelet FAK is a critical regulator of tumor growth after withdrawal of anti-angiogenic therapy Cancer Research. 76: 5048-5048. DOI: 10.1158/1538-7445.Am2016-5048 |
0.43 |
|
| 2016 |
Bayraktar E, Rodriguez-Aguayo C, Mai J, Ivan C, Chavez-Reyes A, Sood AK, Ferrari M, Shen H, Lopez-Berestein G. Abstract 4668: Silencing PTGER3 enhances chemotherapeutic responses Cancer Research. 76: 4668-4668. DOI: 10.1158/1538-7445.Am2016-4668 |
0.529 |
|
| 2016 |
Nilsson MB, Sun H, Diao L, Tong P, Fan Y, Tran H, Liu D, Pena GA, Wang J, Rowe P, Webster A, Lee J, Gomez D, Hong WK, Wistuba I, ... Sood A, et al. Abstract 4662: Beta blockers abrogate EGFR TKI resistance induced by adrenergic receptor-mediated upregulation of IL-6 and modulation of the LKB1/AMPK/mTOR axis Cancer Research. 76: 4662-4662. DOI: 10.1158/1538-7445.Am2016-4662 |
0.302 |
|
| 2016 |
Wen Y, Sood A. Abstract 3529: Immunotherapy targeting folate receptor induces autophagy in ovarian cancer Cancer Research. 76: 3529-3529. DOI: 10.1158/1538-7445.Am2016-3529 |
0.498 |
|
| 2016 |
Wagner MJ, Mitra R, Baze W, Barnhart K, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 2094: Translating EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA) to the clinic Cancer Research. 76: 2094-2094. DOI: 10.1158/1538-7445.Am2016-2094 |
0.305 |
|
| 2016 |
Nick AM, Coleman RL, Ramirez PT, Lu KH, Schmeler KM, Burzawa JK, Soliman PT, Rangel KM, Munsell MF, Sood AK. Personalized surgical therapy for advanced ovarian cancer: R0 resection after neoadjuvant chemotherapy is associated with decreased event-free survival compared with primary cytoreductive surgery Gynecologic Oncology. 141: 181. DOI: 10.1016/J.Ygyno.2016.04.467 |
0.356 |
|
| 2016 |
Nick AM, Ganeshan D, Iyer R, Bhosale P, Munsell MF, Schmeler KM, Burzawa JK, Soliman PT, Coleman RL, Sood AK. Personalizing surgical therapy for advanced ovarian cancer: CT imaging may not predict disease resectability Gynecologic Oncology. 141: 160. DOI: 10.1016/J.Ygyno.2016.04.417 |
0.342 |
|
| 2016 |
Sood AK, Pradeep S, Huang J, Nick AM, Brock S, Hansen J, Previs RA, Hu W, Coleman RL, Jackson DB. Off-target effects of erythropoietin stimulate ovarian cancer via EphB4 Gynecologic Oncology. 141: 45. DOI: 10.1016/J.Ygyno.2016.04.137 |
0.435 |
|
| 2016 |
Matsuo K, Cahoon SS, Kakuda M, Adachi S, Moeini A, Machida H, Garcia J, Ueda Y, Roman LD, Sood AK. Effect of low-dose aspirin on survival outcome of endometrial cancer Gynecologic Oncology. 141: 19. DOI: 10.1016/J.Ygyno.2016.04.075 |
0.366 |
|
| 2016 |
Huang Y, Hu W, Huang J, Pradeep S, Dalton H, Previs R, Hansen J, Nick A, Coleman R, Sood A. Improving hormonal therapy in uterine cancer: Efficacy of onapristone (phosphor-PR) and trametinib Gynecologic Oncology. 141: 19. DOI: 10.1016/J.Ygyno.2016.04.074 |
0.378 |
|
| 2016 |
Hansen JM, Previs RA, Lyons YA, Wang Y, Ivan C, Hu W, Baggerly KA, Sood AK. PTEN loss predicts response to Notch pathway inhibition in endometrial cancer Gynecologic Oncology. 141: 5-6. DOI: 10.1016/J.Ygyno.2016.04.040 |
0.396 |
|
| 2016 |
Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Huang J, Hansen JM, Hu W, Coleman RL, Sood AK. Two to tango: Biological activity and companion predictive markers for a novel dual AKT and P70S6K inhibitor in ovarian and uterine malignancies Gynecologic Oncology. 141: 5. DOI: 10.1016/J.Ygyno.2016.04.039 |
0.627 |
|
| 2016 |
Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer European Journal of Cancer. 56: 131-143. DOI: 10.1016/j.ejca.2015.12.016 |
0.353 |
|
| 2016 |
Lutgendorf SK, Cuneo MG, Schrepf A, Thaker PH, Goodheart M, Cole SW, Slavich GM, Sood AK. Abstract # 1740 Stress and depression levels predict neuroendocrine dynamics in long term ovarian cancer survivors Brain Behavior and Immunity. 57. DOI: 10.1016/J.Bbi.2016.07.037 |
0.361 |
|
| 2015 |
Bullock MD, Silva AM, Kanlikilicer-Unaldi P, Filant J, Rashed MH, Sood AK, Lopez-Berestein G, Calin GA. Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer. Non-Coding Rna. 1: 53-68. PMID 29861415 DOI: 10.3390/Ncrna1010053 |
0.405 |
|
| 2015 |
Cho MS, Rupaimoole R, Choi HJ, Noh K, Chen J, Hu Q, Sood AK, Afshar-Kharghan V. Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition. Journal of Immunology (Baltimore, Md. : 1950). PMID 26718342 DOI: 10.4049/Jimmunol.1501886 |
0.359 |
|
| 2015 |
Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, ... Sood AK, et al. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. PMID 26686630 DOI: 10.1016/J.Celrep.2015.11.047 |
0.724 |
|
| 2015 |
Shinn EH, Valentine A, Jethanandani A, Basen-Engquist K, Fellman B, Urbauer D, Atkinson E, Yusuf SW, Lenihan D, Woods ML, Kies MS, Sood AK, Carmack C, Morrison WH, Gillenwater A, et al. Depression and Oropharynx Cancer Outcome. Psychosomatic Medicine. PMID 26632757 DOI: 10.1097/Psy.0000000000000256 |
0.371 |
|
| 2015 |
Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Beretta L. Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology (Baltimore, Md.). PMID 26599259 DOI: 10.1002/Hep.28367 |
0.332 |
|
| 2015 |
Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram PT, Sehgal V, Lopez-Berestein G, ... ... Sood AK, et al. Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26581245 DOI: 10.1158/1078-0432.Ccr-15-1275 |
0.694 |
|
| 2015 |
Wang R, Stone RL, Kaelber JT, Rochat RH, Nick AM, Vijayan KV, Afshar-Kharghan V, Schmid MF, Dong JF, Sood AK, Chiu W. Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 112: 14266-14271. PMID 26578771 DOI: 10.1073/Pnas.1518628112 |
0.379 |
|
| 2015 |
Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK. Dual metronomic chemotherapy with nab-paclitaxel and topotecan has potent anti-angiogenic activity in ovarian cancer. Molecular Cancer Therapeutics. PMID 26516159 DOI: 10.1158/1535-7163.Mct-14-0630 |
0.708 |
|
| 2015 |
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, ... ... Sood AK, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews. Cancer. 15: 668-79. PMID 26493647 DOI: 10.1038/Nrc4019 |
0.468 |
|
| 2015 |
Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, ... ... Sood AK, et al. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. PMID 26481148 DOI: 10.1016/J.Ccell.2015.09.008 |
0.727 |
|
| 2015 |
Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, ... ... Sood AK, et al. Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell. 28: 529-40. PMID 26461095 DOI: 10.1016/J.Ccell.2015.09.006 |
0.418 |
|
| 2015 |
Huang T, Poole EM, Okereke OI, Kubzansky LD, Eliassen AH, Sood AK, Wang M, Tworoger SS. Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies. Gynecologic Oncology. PMID 26449316 DOI: 10.1016/J.Ygyno.2015.10.004 |
0.357 |
|
| 2015 |
Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, ... ... Sood AK, et al. YAP1 and TAZ Activates mTORC1 Pathway by Regulating Amino Acid Transporters in hepatocellular carcinoma. Hepatology (Baltimore, Md.). PMID 26389641 DOI: 10.1002/Hep.28223 |
0.394 |
|
| 2015 |
Jiang L, Nick AM, Sood AK. Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period? Current Anesthesiology Reports. 5: 250-256. PMID 26388704 DOI: 10.1007/S40140-015-0122-9 |
0.493 |
|
| 2015 |
Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GE. Chitosan nanoparticle-mediated delivery of MiRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. PMID 26313360 DOI: 10.18632/Oncotarget.4971 |
0.354 |
|
| 2015 |
Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. PMID 26301456 DOI: 10.1002/Cncr.29392 |
0.463 |
|
| 2015 |
Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AK. Sympathetic nervous system regulation of the tumour microenvironment. Nature Reviews. Cancer. 15: 563-72. PMID 26299593 DOI: 10.1038/Nrc3978 |
0.432 |
|
| 2015 |
Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Gharpure KM, Pradeep S, Zand B, Previs RA, Hansen JM, Ivan C, ... ... Sood AK, et al. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene. PMID 26257064 DOI: 10.1038/Onc.2015.302 |
0.749 |
|
| 2015 |
Matsuo K, Hasegawa K, Yoshino K, Murakami R, Hisamatsu T, Stone RL, Previs RA, Hansen JM, Ikeda Y, Miyara A, Hiramatsu K, Enomoto T, Fujiwara K, Matsumura N, Konishi I, ... ... Sood AK, et al. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. European Journal of Cancer (Oxford, England : 1990). 51: 1978-88. PMID 26238017 DOI: 10.1016/J.Ejca.2015.07.012 |
0.308 |
|
| 2015 |
Reyes-González JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mejía PE. Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Molecular Cancer Therapeutics. 14: 2260-9. PMID 26227489 DOI: 10.1158/1535-7163.Mct-14-0801 |
0.707 |
|
| 2015 |
Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills GB, ... ... Sood AK, et al. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene. PMID 26212011 DOI: 10.1038/Onc.2015.279 |
0.446 |
|
| 2015 |
Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. Jama Oncology. 1: 486-94. PMID 26181259 DOI: 10.1001/Jamaoncol.2015.1432 |
0.406 |
|
| 2015 |
Gharpure KM, Wu SY, Li C, Lopez-Berestein G, Sood AK. Nanotechnology: Future of Oncotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3121-30. PMID 26180057 DOI: 10.1158/1078-0432.Ccr-14-1189 |
0.387 |
|
| 2015 |
Graybill W, Sood AK, Monk BJ, Coleman RL. State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecologic Oncology. 138: 223-6. PMID 26166806 DOI: 10.1016/J.Ygyno.2015.07.008 |
0.428 |
|
| 2015 |
Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, et al. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. Plos One. 10: e0131833. PMID 26146988 DOI: 10.1371/Journal.Pone.0131833 |
0.486 |
|
| 2015 |
Ravoori MK, Nishimura M, Singh SP, Lu C, Han L, Hobbs BP, Pradeep S, Choi HJ, Bankson JA, Sood AK, Kundra V. Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. Plos One. 10: e0131095. PMID 26098849 DOI: 10.1371/Journal.Pone.0131095 |
0.372 |
|
| 2015 |
Davis LZ, Slavich GM, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Farley DM, Markon KE, Penedo FJ, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK. Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer. Cancer. PMID 26096769 DOI: 10.1002/Cncr.29516 |
0.485 |
|
| 2015 |
Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, ... ... Sood AK, et al. The ZNF304-integrin axis protects against anoikis in cancer. Nature Communications. 6: 7351. PMID 26081979 DOI: 10.1038/Ncomms8351 |
0.474 |
|
| 2015 |
Matsuo K, Hom MS, Moeini A, Machida H, Takeshima N, Roman LD, Sood AK. Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer. Gynecologic Oncology. 138: 332-8. PMID 26013698 DOI: 10.1016/J.Ygyno.2015.05.019 |
0.455 |
|
| 2015 |
Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, ... ... Sood AK, et al. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. Journal of the National Cancer Institute. 107. PMID 25995442 DOI: 10.1093/Jnci/Djv108 |
0.418 |
|
| 2015 |
Bayer JL, Spitz DR, Christensen D, McCormick ML, Farley D, DeGeest K, Damoush L, Aust S, Sood AK, Lutgendorf SK. Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma. Brain, Behavior, and Immunity. PMID 25989110 DOI: 10.1016/J.Bbi.2015.04.019 |
0.437 |
|
| 2015 |
Choi HH, Guma S, Fang L, Phan L, Ivan C, Baggerly K, Sood A, Lee MH. Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis. Cell Cycle (Georgetown, Tex.). 14: 2265-73. PMID 25945542 DOI: 10.1080/15384101.2015.1046655 |
0.318 |
|
| 2015 |
Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 520: 697-701. PMID 25901683 DOI: 10.1038/Nature14418 |
0.469 |
|
| 2015 |
Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, ... ... Sood AK, et al. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3286-97. PMID 25878333 DOI: 10.1158/1078-0432.Ccr-14-1953 |
0.324 |
|
| 2015 |
Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Molecular Cancer Therapeutics. 14: 1466-75. PMID 25833835 DOI: 10.1158/1535-7163.Mct-14-1077 |
0.703 |
|
| 2015 |
Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PT. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecologic Oncology. 137: 553-8. PMID 25827290 DOI: 10.1016/J.Ygyno.2015.03.049 |
0.317 |
|
| 2015 |
Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, ... Sood AK, et al. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget. 6: 4266-73. PMID 25738355 DOI: 10.18632/Oncotarget.2887 |
0.703 |
|
| 2015 |
Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a personalized surgical approach to ovarian cancer. Nature Reviews. Clinical Oncology. 12: 239-45. PMID 25707631 DOI: 10.1038/Nrclinonc.2015.26 |
0.347 |
|
| 2015 |
Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJ, ... ... Sood AK, et al. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nature Cell Biology. 17: 311-21. PMID 25686251 DOI: 10.1038/Ncb3110 |
0.315 |
|
| 2015 |
Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, et al. STAMP2 increases oxidative stress and is critical for prostate cancer. Embo Molecular Medicine. 7: 315-31. PMID 25680860 DOI: 10.15252/Emmm.201404181 |
0.377 |
|
| 2015 |
Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Advanced Drug Delivery Reviews. PMID 25666164 DOI: 10.1016/J.Addr.2015.01.007 |
0.376 |
|
| 2015 |
Schrepf A, Thaker PH, Goodheart MJ, Bender D, Slavich GM, Dahmoush L, Penedo F, DeGeest K, Mendez L, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK. Diurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology. 53: 256-67. PMID 25647344 DOI: 10.1016/J.Psyneuen.2015.01.010 |
0.498 |
|
| 2015 |
Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot C, ... Sood AK, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. PMID 25639871 DOI: 10.1038/Onc.2014.469 |
0.376 |
|
| 2015 |
Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del C Monroig P, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, ... ... Sood AK, et al. Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2127-37. PMID 25595279 DOI: 10.1158/1078-0432.Ccr-14-2279 |
0.441 |
|
| 2015 |
Sun Y, Guo F, Bagnoli M, Xue FX, Sun BC, Shmulevich I, Mezzanzanica D, Chen KX, Sood AK, Yang D, Zhang W. Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chinese Journal of Cancer. 34: 28-40. PMID 25556616 DOI: 10.5732/Cjc.014.10284 |
0.466 |
|
| 2015 |
Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Reviews. 34: 19-40. PMID 25544368 DOI: 10.1007/S10555-014-9538-9 |
0.424 |
|
| 2015 |
Srivastava A, Filant J, Moxley KM, Sood A, McMeekin S, Ramesh R. Exosomes: a role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment. Current Gene Therapy. 15: 182-92. PMID 25537774 DOI: 10.2174/1566523214666141224100612 |
0.337 |
|
| 2015 |
Yang X, Shen F, Hu W, Coleman RL, Sood AK. New ways to successfully target tumor vasculature in ovarian cancer. Current Opinion in Obstetrics & Gynecology. 27: 58-65. PMID 25502429 DOI: 10.1097/Gco.0000000000000136 |
0.48 |
|
| 2015 |
Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs RA, Pecot CV, Crane EK, Hu W, Lutgendorf SK, Afshar-Kharghan V, ... Sood AK, et al. Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 602-10. PMID 25473001 DOI: 10.1158/1078-0432.Ccr-14-0870 |
0.309 |
|
| 2015 |
Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, ... Sood AK, et al. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 448-59. PMID 25416196 DOI: 10.1158/1078-0432.Ccr-14-1578 |
0.464 |
|
| 2015 |
Previs RA, Coleman RL, Harris AL, Sood AK. Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 955-61. PMID 25388163 DOI: 10.1158/1078-0432.Ccr-14-0809 |
0.363 |
|
| 2015 |
Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. The Journal of Pathology. 235: 25-36. PMID 25230372 DOI: 10.1002/Path.4443 |
0.32 |
|
| 2015 |
Feng S, Kroll MH, Nick AM, Sood A, Afshar-Kharghan V. Platelet Function in Ovarian Cancer Blood. 126: 4656-4656. DOI: 10.1182/Blood.V126.23.4656.4656 |
0.382 |
|
| 2015 |
Vivas-Mejia PE, Reyes j, Sood AK. Abstract B45: c-MYC is a potential therapeutic target for cisplatin-resistant ovarian cancer Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-B45 |
0.477 |
|
| 2015 |
Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang T, Xie X, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y. Abstract P6-17-01: MicroRNA-34a suppresses breast cancer bone metastasis by inhibiting osteoclastogenesis and targeting tgif2 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-17-01 |
0.32 |
|
| 2015 |
Wu SY, Filant J, McGuire M, Rupaimoole R, Pradeep S, Unruh A, Shelley H, Ivan C, Dennis R, Rodriguez-Aguayo C, Sehgal V, Miyake T, Nagaraja A, Gharpure K, Armaiz G, ... Sood A, et al. Abstract 5466: Integrative TCGA analyses identify Basonuclin1 (BNC1) as a key mediator for platinum resistance Cancer Research. 75: 5466-5466. DOI: 10.1158/1538-7445.Am2015-5466 |
0.503 |
|
| 2015 |
Leung CS, Yeung T, Yip K, Wong K, Sood AK, Birrer MJ, Mok SC. Abstract 4184: CAF-derived MFAP5 promotes tumor angiogenesis and confers paclitaxel resistance in high-grade serous ovarian cancer Cancer Research. 75: 4184-4184. DOI: 10.1158/1538-7445.Am2015-4184 |
0.55 |
|
| 2015 |
Granados-Principal S, Liu Y, Rodriguez-Aguayo C, Sood AK, Chang JC. Abstract 4086: HMG Box Domain Containing 3 (HMGXB3), a novel TGFβ-induced cancer gene that influences cancer stem cells and metastasis in triple negative breast cancer Cancer Research. 75: 4086-4086. DOI: 10.1158/1538-7445.Am2015-4086 |
0.434 |
|
| 2015 |
Napoli M, Venkatanarayan A, Raulji P, Abbas HA, Norton W, Sood AK, Lopez-Berestein G, Tsai KY, Coarfa C, Gunaratne PH, Flores ER. Abstract 3975: Pharmacologic inhibition of the ΔNp63/DGCR8 axis as a novel therapeutic strategy for p53-deficient and mutant tumors Cancer Research. 75: 3975-3975. DOI: 10.1158/1538-7445.Am2015-3975 |
0.402 |
|
| 2015 |
Wen Y, Sood AK. Abstract 3817: Suicidal autophagy induced by immunotherapy targeting folate receptor in ovarian cancer Cancer Research. 75: 3817-3817. DOI: 10.1158/1538-7445.Am2015-3817 |
0.529 |
|
| 2015 |
Nagaraja AS, Dorniak P, Sadaoui N, Armaiz-Pena G, Zand B, Wu SY, Allen JK, Rupaimoole R, Rodriguez-Aguayo C, Pradeep S, Tan L, Previs RA, Hansen JM, Yang P, Lopez-Berestein G, ... ... Sood AK, et al. Abstract 3368: Sustained adrenergic signaling activates pro-inflammatory prostaglandin network in ovarian carcinoma Cancer Research. 75: 3368-3368. DOI: 10.1158/1538-7445.Am2015-3368 |
0.704 |
|
| 2015 |
Raghavan PC, Pradeep S, Lu Y, Sood A, Mills G. Abstract 3072: miR-551b amplification regulates STAT3 expression and resistance to anoikis of ovarian cancer cells Cancer Research. 75: 3072-3072. DOI: 10.1158/1538-7445.Am2015-3072 |
0.466 |
|
| 2015 |
Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Dorniak P, Previs R, Sadaoui N, Stone R, Matsuo K, Dalton HJ, Lutgendorf SK, Sood AK, Lopez-Berestein G. Abstract 2359: Adrenergic regulation of MCP-1 leads to enhanced macrophage recruitment and ovarian carcinoma growth Cancer Research. 75: 2359-2359. DOI: 10.1158/1538-7445.Am2015-2359 |
0.717 |
|
| 2015 |
Liu Y, Choi DS, Grandos-Principal S, Qian W, Burey L, Wong H, Rodriguez-Aguayo C, Sood A, Li Z, Wong S, Weiss H, Dave B, Landis M, Chang JC. Abstract 2312: Identifying novel cancer stem cell target for triple-negative breast cancer Cancer Research. 75: 2312-2312. DOI: 10.1158/1538-7445.Am2015-2312 |
0.5 |
|
| 2015 |
Gharpure KM, Tucker SL, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, ... Sood A, et al. Abstract 2273: Mechanistic and functional implications of FABP4 in ovarian cancer metastasis Cancer Research. 75: 2273-2273. DOI: 10.1158/1538-7445.Am2015-2273 |
0.482 |
|
| 2015 |
Hansen JM, Baggerly K, Wang Y, Ivan C, Wu S, Previs R, Zand B, Dalton H, Hu W, Coleman RL, Sood AK. Abstract 2165: Concurrent BRCA2 and PTEN mutations are associated with improved survival in endometrioid endometrial cancer Cancer Research. 75: 2165-2165. DOI: 10.1158/1538-7445.Am2015-2165 |
0.359 |
|
| 2015 |
Pradeep S, Huang J, Mora E, Nick A, Cho M, Wu S, Rupaimoole R, Xiong C, Li C, Lopez-Berestein G, Jackson D, Sood A. Abstract 1952: Adverse effects of erythropoietin stimulates tumor growth via EphB4 Cancer Research. 75: 1952-1952. DOI: 10.1158/1538-7445.Am2015-1952 |
0.454 |
|
| 2015 |
Rupaimole R, Previs R, Lee J, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison J, Rodriguez-Aguayo C, Calin GA, Mills G, Zhang W, Lopez-Berestein G, Bhattacharya P, Sood AK. Abstract 142: SiRNA therapy against novel lncRNA NRCP: shutting down the fuel for cancer cells Cancer Research. 75: 142-142. DOI: 10.1158/1538-7445.Am2015-142 |
0.406 |
|
| 2015 |
Yang L, Achreja A, Moss T, Baddour J, Stilles K, Chiba L, Kim SH, Morse J, Marini J, Sood AK, Ram PT, Nagrath D. Abstract 1208: Glutamine modulates cellular NAD+/NADH homeostasis thereby regulating cancer metastasis, drug sensitivity in cancer cells Cancer Research. 75: 1208-1208. DOI: 10.1158/1538-7445.Am2015-1208 |
0.512 |
|
| 2015 |
Previs RA, Moss TJ, Zand B, Rupaimoole R, Dalton HJ, Hansen JM, Armaiz-Pena G, Lutgendorf S, Coleman RL, Bhattacharya P, Ram P, Sood AK. Abstract 1199: Systems-based approach identifies altered carbohydrate metabolism as a predictor of a malignant phenotype in ovarian cancer Cancer Research. 75: 1199-1199. DOI: 10.1158/1538-7445.Am2015-1199 |
0.658 |
|
| 2015 |
Choi DS, Yi L, Rodriguez-Aguayo C, Dave B, Wong STC, Sood AK, Chang JC. Abstract LB-C09: Hematological and Neurological Expressed 1-Like (HN1L) is a Novel Therapeutic Target for Triple Negative Breast Cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-C09 |
0.459 |
|
| 2015 |
Fleming ND, Coleman RL, Tung CS, Munsell MF, Sood AK. Phase II trial of bevacizumab with carboplatin and dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer Gynecologic Oncology. 137: 79. DOI: 10.1016/J.Ygyno.2015.01.194 |
0.362 |
|
| 2015 |
Zand B, Previs R, Zacharias N, Rupaimoole R, Dalton H, Hansen J, Rodriguez-Aguayo C, Guindani M, Lopez-Berestein G, Bhattacharya P, Sood A. Role of increased n-acetylaspartate levels in epithelial ovarian cancer Gynecologic Oncology. 137: 68. DOI: 10.1016/J.Ygyno.2015.01.161 |
0.422 |
|
| 2015 |
Previs R, Moss T, Zand B, Rupaimoole R, Dalton H, Hansen J, Armaiz-Pena G, Lutgendorf S, Coleman R, Bhattacharya P, Ram P, Sood A. Fuel for the fire: Connecting genomics with metabolomics in ovarian cancer Gynecologic Oncology. 137: 67. DOI: 10.1016/J.Ygyno.2015.01.157 |
0.647 |
|
| 2015 |
Sood AK, Huang J, Hu W, Previs RA, Dalton HJ, Hansen JM, Sun Y, Nick AM, Broaddus R, Coleman RL. Molecular predictors of response to EphA2 targeted therapy in uterine cancer Gynecologic Oncology. 137: 59. DOI: 10.1016/J.Ygyno.2015.01.137 |
0.398 |
|
| 2015 |
Previs RA, Thanapprapasr D, Hu W, Rupaimoole R, Huang J, Dalton HJ, Ali R, Armaiz-Pena GN, Hansen JM, Zand B, Coleman RL, Sood AK. The FAK of uterine cancer: PTEN expression predicts response of uterine cancer to focal adhesion kinase inhibition Gynecologic Oncology. 137: 59. DOI: 10.1016/J.Ygyno.2015.01.136 |
0.684 |
|
| 2015 |
Hansen JM, Baggerly KA, Wang Y, Wu S, Previs RA, Zand B, Dalton HJ, Hu W, Coleman RL, Sood AK. Homologous recombination deficiency in endometrioid uterine cancer: An unrecognized phenomenon Gynecologic Oncology. 137: 21. DOI: 10.1016/J.Ygyno.2015.01.048 |
0.434 |
|
| 2015 |
Nick AM, Coleman RL, Ramirez PT, Schmeler KM, Soliman PT, Lu KH, Burzawa JK, Sood AK. Personalized surgical therapy for advanced ovarian cancer Gynecologic Oncology. 137: 10. DOI: 10.1016/J.Ygyno.2015.01.022 |
0.411 |
|
| 2015 |
Lutgendorf S, Thaker P, Slavich G, Goodheart M, Bender D, Dahmoush L, Lubaroff D, Penedo F, DeGeest K, Arevalo J, Sood A, Cole S. Beta-adrenergic activation of Epithelial-Mesenchymal Transition in ovarian cancer Brain, Behavior, and Immunity. 49: e1-e2. DOI: 10.1016/J.Bbi.2015.06.028 |
0.504 |
|
| 2015 |
Taylor M, Coleman RL, Sood AK. The Role of Angiogenesis in Cancer Translational Cancer Research. 64-71. DOI: 10.1002/9781118468678.Ch6 |
0.466 |
|
| 2014 |
Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, ... ... Sood AK, et al. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell. 26: 863-79. PMID 25490449 DOI: 10.1016/J.Ccell.2014.10.010 |
0.328 |
|
| 2014 |
Tamir A, Jag U, Sarojini S, Schindewolf C, Tanaka T, Gharbaran R, Patel H, Sood A, Hu W, Patwa R, Blake P, Chirina P, Oh Jeong J, Lim H, Goy A, et al. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. Journal of Ovarian Research. 7: 109. PMID 25477184 DOI: 10.1186/S13048-014-0109-Z |
0.302 |
|
| 2014 |
Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, et al. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nature Communications. 5: 5671. PMID 25476932 DOI: 10.1038/Ncomms6671 |
0.336 |
|
| 2014 |
van den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S, Starmans MH, Yao CQ, Ivan M, Ivan C, Pecot CV, ... ... Sood AK, et al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nature Communications. 5: 5203. PMID 25351418 DOI: 10.1038/Ncomms6203 |
0.401 |
|
| 2014 |
Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, ... ... Sood AK, et al. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nature Communications. 5: 5202. PMID 25351346 DOI: 10.1038/Ncomms6202 |
0.611 |
|
| 2014 |
Chaoul A, Milbury K, Sood AK, Prinsloo S, Cohen L. Mind-body practices in cancer care. Current Oncology Reports. 16: 417. PMID 25325936 DOI: 10.1007/S11912-014-0417-X |
0.356 |
|
| 2014 |
Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, ... ... Sood AK, et al. Therapeutic silencing of KRAS using systemically delivered siRNAs. Molecular Cancer Therapeutics. 13: 2876-85. PMID 25281617 DOI: 10.1158/1535-7163.Mct-14-0074 |
0.472 |
|
| 2014 |
Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature Communications. 5: 5092. PMID 25277212 DOI: 10.1038/Ncomms6092 |
0.725 |
|
| 2014 |
Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus RR, Zhang W. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. Journal of the National Cancer Institute. 106. PMID 25214561 DOI: 10.1093/Jnci/Dju245 |
0.318 |
|
| 2014 |
Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, ... ... Sood AK, et al. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Molecular Cancer Therapeutics. 13: 2583-94. PMID 25193509 DOI: 10.1158/1535-7163.Mct-14-0028 |
0.661 |
|
| 2014 |
Han C, Liu Y, Wan G, Choi HJ, Zhao L, Ivan C, He X, Sood AK, Zhang X, Lu X. The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. Cell Reports. 8: 1447-60. PMID 25176654 DOI: 10.1016/J.Celrep.2014.07.058 |
0.328 |
|
| 2014 |
Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ET. Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prevention Research (Philadelphia, Pa.). 7: 973-92. PMID 25060262 DOI: 10.1158/1940-6207.Capr-14-0079 |
0.451 |
|
| 2014 |
Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, ... Sood AK, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 26: 77-91. PMID 25026212 DOI: 10.1016/J.Ccr.2014.05.002 |
0.517 |
|
| 2014 |
Davis AN, Afshar-Kharghan V, Sood AK. Platelet effects on ovarian cancer. Seminars in Oncology. 41: 378-84. PMID 25023353 DOI: 10.1053/J.Seminoncol.2014.04.004 |
0.416 |
|
| 2014 |
Rytelewski M, Tong JG, Buensuceso A, Leong HS, Maleki Vareki S, Figueredo R, Di Cresce C, Wu SY, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers AF, et al. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. Molecular Oncology. 8: 1429-40. PMID 24974076 DOI: 10.1016/J.Molonc.2014.05.017 |
0.506 |
|
| 2014 |
Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, ... ... Sood A, et al. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Research. 74: 4822-35. PMID 24970481 DOI: 10.1158/0008-5472.Can-14-0584 |
0.397 |
|
| 2014 |
Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, ... Sood AK, et al. Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecologic Oncology. 134: 6-9. PMID 24952408 DOI: 10.1016/J.Ygyno.2014.04.042 |
0.409 |
|
| 2014 |
Wu SY, Lopez-Berestein G, Calin GA, Sood AK. RNAi therapies: drugging the undruggable. Science Translational Medicine. 6: 240ps7. PMID 24920658 DOI: 10.1126/Scitranslmed.3008362 |
0.357 |
|
| 2014 |
Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AK. Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biology & Therapy. 15: 1061-7. PMID 24841852 DOI: 10.4161/Cbt.29184 |
0.489 |
|
| 2014 |
Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, ... Sood AK, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Molecular Systems Biology. 10: 728. PMID 24799285 DOI: 10.1002/Msb.20134892 |
0.73 |
|
| 2014 |
Matsuo K, Yoshino K, Hiramatsu K, Banzai C, Hasegawa K, Yasuda M, Nishimura M, Sheridan TB, Ikeda Y, Shiki Y, Mabuchi S, Enomoto T, Kimura T, Fujiwara K, Roman LD, ... Sood AK, et al. Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer. Obstetrics and Gynecology. 123: 957-65. PMID 24785846 DOI: 10.1097/Aog.0000000000000240 |
0.419 |
|
| 2014 |
Noh KH, Kim SH, Kim JH, Song KH, Lee YH, Kang TH, Han HD, Sood AK, Ng J, Kim K, Sonn CH, Kumar V, Yee C, Lee KM, Kim TW. API5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Research. 74: 3556-66. PMID 24769442 DOI: 10.1158/0008-5472.Can-13-3225 |
0.353 |
|
| 2014 |
Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, ... ... Sood AK, et al. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3280-8. PMID 24756370 DOI: 10.1158/1078-0432.Ccr-14-0445 |
0.376 |
|
| 2014 |
Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, ... ... Sood AK, et al. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biology & Therapy. 15: 919-29. PMID 24755674 DOI: 10.4161/Cbt.28882 |
0.703 |
|
| 2014 |
Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, ... Sood AK, et al. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Molecular Cancer Therapeutics. 13: 1750-7. PMID 24755199 DOI: 10.1158/1535-7163.Mct-13-0930 |
0.692 |
|
| 2014 |
Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, ... Sood AK, et al. Notch3 pathway alterations in ovarian cancer. Cancer Research. 74: 3282-93. PMID 24743243 DOI: 10.1158/0008-5472.Can-13-2066 |
0.478 |
|
| 2014 |
Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. European Journal of Cancer (Oxford, England : 1990). 50: 1638-48. PMID 24709487 DOI: 10.1016/J.Ejca.2014.03.005 |
0.368 |
|
| 2014 |
Joshi HP, Subramanian IV, Schnettler EK, Ghosh G, Rupaimoole R, Evans C, Saluja M, Jing Y, Cristina I, Roy S, Zeng Y, Shah VH, Sood AK, Ramakrishnan S. Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America. 111: 5331-6. PMID 24706848 DOI: 10.1073/Pnas.1317242111 |
0.39 |
|
| 2014 |
Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, ... ... Sood AK, et al. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Reports. 7: 488-500. PMID 24703838 DOI: 10.1016/J.Celrep.2014.03.009 |
0.475 |
|
| 2014 |
Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Reviews. 33: 231-69. PMID 24696047 DOI: 10.1007/S10555-014-9498-0 |
0.367 |
|
| 2014 |
Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD, Im DD, Rosenshein NB, Roman LD, Sood AK. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecologic Oncology. 133: 473-9. PMID 24674832 DOI: 10.1016/J.Ygyno.2014.03.563 |
0.414 |
|
| 2014 |
Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, ... Sood AK, et al. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2740-50. PMID 24634380 DOI: 10.1158/1078-0432.Ccr-13-2507 |
0.495 |
|
| 2014 |
Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, ... ... Sood AK, et al. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications. 5: 3459. PMID 24619206 DOI: 10.1038/Ncomms4459 |
0.651 |
|
| 2014 |
Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, ... ... Sood AK, et al. Autocrine effects of tumor-derived complement. Cell Reports. 6: 1085-95. PMID 24613353 DOI: 10.1016/J.Celrep.2014.02.014 |
0.499 |
|
| 2014 |
Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, Parker Kerrigan BC, Shmulevich I, Chen K, Sood AK, Xue F, Zhang W. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. The Journal of Pathology. 233: 308-18. PMID 24604117 DOI: 10.1002/Path.4348 |
0.375 |
|
| 2014 |
Guo F, Parker Kerrigan BC, Yang D, Hu L, Shmulevich I, Sood AK, Xue F, Zhang W. Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions. Journal of Hematology & Oncology. 7: 19. PMID 24598126 DOI: 10.1186/1756-8722-7-19 |
0.338 |
|
| 2014 |
Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK. Monocyte subpopulations in angiogenesis. Cancer Research. 74: 1287-93. PMID 24556724 DOI: 10.1158/0008-5472.Can-13-2825 |
0.683 |
|
| 2014 |
Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DS, Mills GB, Sood A, Lee JS. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Research. 34: 811-7. PMID 24511017 |
0.389 |
|
| 2014 |
Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, ... ... Sood AK, et al. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1846-55. PMID 24486585 DOI: 10.1158/1078-0432.Ccr-13-2141 |
0.364 |
|
| 2014 |
Cata JP, Villarreal J, Keerty D, Thakar DR, Liu DD, Sood AK, Gottumukkala V. Perioperative beta-blocker use and survival in lung cancer patients. Journal of Clinical Anesthesia. 26: 106-17. PMID 24480297 DOI: 10.1016/J.Jclinane.2013.10.004 |
0.342 |
|
| 2014 |
Zhaorigetu S, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G, Walton BL. Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. Journal of Liposome Research. 24: 182-90. PMID 24443972 DOI: 10.3109/08982104.2013.863208 |
0.312 |
|
| 2014 |
Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Advanced Drug Delivery Reviews. 66: 110-6. PMID 24384374 DOI: 10.1016/J.Addr.2013.12.008 |
0.426 |
|
| 2014 |
Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN, Eblen ST. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 35: 1100-9. PMID 24379240 DOI: 10.1093/Carcin/Bgt489 |
0.446 |
|
| 2014 |
Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecologic Oncology. 132: 166-75. PMID 24183729 DOI: 10.1016/J.Ygyno.2013.10.027 |
0.325 |
|
| 2014 |
Cho MS, Hu Q, Rupaimoole R, Sood A, Afshar-Kharghan V. Complement Component 3 (C3) Is a Mediator of Epithelial-Mesenchymal Transition (EMT) Blood. 124: 1421-1421. DOI: 10.1182/Blood.V124.21.1421.1421 |
0.37 |
|
| 2014 |
Pecot C, Wu S, Bellister S, Bhattacharya R, Maharaj A, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Lopez-Berestein G, Ellis LM, Sood A. Abstract B47: Therapeutic KRAS silencing in lung and colon cancer models Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-B47 |
0.452 |
|
| 2014 |
Gharpure KM, Chu KS, Bowerman C, Miyake T, Pradeep S, Mangala LS, Han H, Rupaimoole R, Wu SY, Dalton HJ, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK. Abstract 5403: Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer Cancer Research. 74: 5403-5403. DOI: 10.1158/1538-7445.Am2014-5403 |
0.392 |
|
| 2014 |
Shoshan E, Mobley A, Braeuer R, Kamiya T, Huang L, Vasquez M, Jeong LH, kim SJ, Calin G, Sood A, Markel G, Fidler I, Bar-Eli M. Abstract 4969: Hypo adenosine-to-inosine editing of microRNA-455 promotes melanoma metastasis Cancer Research. 74: 4969-4969. DOI: 10.1158/1538-7445.Am2014-4969 |
0.344 |
|
| 2014 |
Pradeep S, Kim SW, Wu S, Masato N, Miyake T, Hyun-Jin C, Rupaimoole R, Liu J, Fidler I, Lopez G, Sood A. Abstract 4954: Hematogenous metastasis of ovarian cancer: Re-thinking mode of spread Cancer Research. 74: 4954-4954. DOI: 10.1158/1538-7445.Am2014-4954 |
0.529 |
|
| 2014 |
Jiang D, Mangala LS, Wang H, Wu S, Rao LG, Rodriguez-Aguayo C, Pradeep S, Volk DE, Lopez-Berestein G, Sood AK. Abstract 4468: Tumor vasculature targeting using cell-specific thioaptamer decorated chitosan nanoparticle Cancer Research. 74: 4468-4468. DOI: 10.1158/1538-7445.Am2014-4468 |
0.429 |
|
| 2014 |
Chaluvally-Raghavan P, Zhang F, Liu W, Tyler M, Yu S, Pradeep S, Ram P, Lu Y, Sood A, Mills G. Abstract 4396: MicroRNA MIR551B amplified at 3q26.2 locus activate c-KIT expression and causes resistance to anoikis of ovarian cancer cells Cancer Research. 74: 4396-4396. DOI: 10.1158/1538-7445.Am2014-4396 |
0.492 |
|
| 2014 |
Reyes-González JM, Armaiz GN, Mangala LS, Valiyeva F, Pradeep S, Sood AK, Vivas-Mejía PE. Abstract 3761: Nanoliposomal c-MYC-siRNA inhibitsin vivotumor growth of cisplatin-resistant ovarian cancer Cancer Research. 74: 3761-3761. DOI: 10.1158/1538-7445.Am2014-3761 |
0.51 |
|
| 2014 |
Rupaimoole R, Ivan C, Pecot C, Wu S, Pradeep S, Zand B, Nagaraja A, Gharpure K, Dalton H, Sadaoui N, Zhang W, Lopez-Berestein G, Sood A. Abstract 3532: Hypoxia is a master regulator of Drosha- and Dicer-dependent miRNA biogenesis in cancer Cancer Research. 74: 3532-3532. DOI: 10.1158/1538-7445.Am2014-3532 |
0.38 |
|
| 2014 |
Sadaoui NC, Armaiz-Pena GN, Nagaraja AS, Rupaimoole R, Previs RA, Dalton HJ, Lingegowda MS, Ramondetta LM, Sood AK, Lutgendorf SK, Cole SW. Abstract 3511: Sustained adrenergic signaling promotes cervical cancer progression Cancer Research. 74: 3511-3511. DOI: 10.1158/1538-7445.Am2014-3511 |
0.703 |
|
| 2014 |
Yang L, Moss TJ, Marini JC, Mangala S, Wahlig S, Win J, Su D, Sood AK, Ram PT, Nagrath D. Abstract 3377: Glutamine mediated aggressiveness and drug sensitivity in ovarian cancer cells Cancer Research. 74: 3377-3377. DOI: 10.1158/1538-7445.Am2014-3377 |
0.461 |
|
| 2014 |
Previs RA, Ivan C, Dalton HJ, Davis AN, Bottsford-Miller JN, Zand B, McGuire MH, Armaiz-Pena GN, Coleman RL, Baggerly KA, Sood AK. Abstract 3340: Exploiting the non-overlapping dysregulation of Notch and PI3K/AKT signaling pathways as a guide for personalizing uterine cancer therapy Cancer Research. 74: 3340-3340. DOI: 10.1158/1538-7445.Am2014-3340 |
0.698 |
|
| 2014 |
Davis AN, Lin-Liu YG, Previs RA, Dalton HJ, Zand B, Bottsford-Miller J, Coleman R, Sood AK. Abstract 2995: Metronomic albumin-bound paclitaxel and topotecan has potent antitumor activity in ovarian cancer Cancer Research. 74: 2995-2995. DOI: 10.1158/1538-7445.Am2014-2995 |
0.492 |
|
| 2014 |
Huang J, Hu W, Dalton HJ, Bottsford-Miller J, Coleman RL, Jaffe RB, Sood AK. Abstract 2993: Dll4 inhibition plus aflibercept markedly reduces ovarian tumor burden and ascites Cancer Research. 74: 2993-2993. DOI: 10.1158/1538-7445.Am2014-2993 |
0.472 |
|
| 2014 |
Gonzalez-Villasana V, Rodriguez-Aguayo C, Fuentes-Mattei E, Pradeep S, Ivan C, Sood AK, Lopez-Berestein G. Abstract 2992: Zoledronic acid inhibits angiogenesis through Rac1 inactivation in ovarian cancer Cancer Research. 74: 2992-2992. DOI: 10.1158/1538-7445.Am2014-2992 |
0.475 |
|
| 2014 |
Dalton HJ, Reusser NM, Zien A, Jackson D, Previs R, Rupaimoole R, Zand B, Lopez-Berestein G, Coleman RL, Sood AK. Abstract 2983: Bisphosphonates: New strategies for targeting angiogenesis in ovarian cancer Cancer Research. 74: 2983-2983. DOI: 10.1158/1538-7445.Am2014-2983 |
0.519 |
|
| 2014 |
Dalton HJ, Pradeep S, Armaiz-Pena GN, Previs R, Davis A, Rupaimoole R, Zand B, Hailemichael Y, Overwijk WW, Lopez-Berestein G, Sood AK. Abstract 2982: Macrophages modulate adaptive resistance to anti-angiogenic therapy Cancer Research. 74: 2982-2982. DOI: 10.1158/1538-7445.Am2014-2982 |
0.666 |
|
| 2014 |
Nagaraja AS, Armaiz-Pena G, Allen J, Sadaoui NC, Zand B, Yang P, Tan L, Cole S, Lutgendorf S, Sood AK. Abstract 158: Sustained adrenergic signaling activates pro-inflammatory networks in ovarian carcinoma Cancer Research. 74: 158-158. DOI: 10.1158/1538-7445.Am2014-158 |
0.703 |
|
| 2014 |
Shah M, Lopez GB, Sood A, Calin G. Abstract 1455: Therapeutic synergy between novel tumor suppressor miR-520d-3p and EphA2-targeting siRNA in ovarian cancer Cancer Research. 74: 1455-1455. DOI: 10.1158/1538-7445.Am2014-1455 |
0.45 |
|
| 2014 |
Wen Y, Graybill WS, Sood A. Abstract 1330: Immunotherapy targeting folate receptor induces autophagy in ovarian cancer Cancer Research. 74: 1330-1330. DOI: 10.1158/1538-7445.Am2014-1330 |
0.494 |
|
| 2014 |
Armaiz-Pena GN, Nagaraja AS, Allen JK, Sadaoui NC, Rupaimoole R, wu sY, Pradeep S, Han HD, Zand B, Dalton H, Previs R, Taylor M, Bottsford-Miller J, Mangala LS, Rodriguez-Aguayo C, ... ... Sood AK, et al. Abstract 1062: Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction Cancer Research. 74: 1062-1062. DOI: 10.1158/1538-7445.Am2014-1062 |
0.705 |
|
| 2014 |
Leung CS, Yeung T, Yip K, Wong K, Sood AK, Birrer MJ, Mok SC. Abstract 1029: CAF-derived MFAP5 promotes ovarian tumor angiogenesis through calcium dependent LPP signaling pathway Cancer Research. 74: 1029-1029. DOI: 10.1158/1538-7445.Am2014-1029 |
0.494 |
|
| 2014 |
King ER, Coleman RL, Urbauer D, Fellman B, Sood AK, Nick AM. Out with the old and in with the neoadjuvant: Changes and influences in ovarian cancer practice patterns among Society of Gynecologic Oncology (SGO) members Gynecologic Oncology. 133: 143. DOI: 10.1016/J.Ygyno.2014.03.374 |
0.393 |
|
| 2014 |
Previs RA, Ivan C, Dalton HJ, Davis AN, Bottsford-Miller JN, Zand B, Coleman RL, Baggerly KA, Sood AK. Taking it up a Notch: Implications for outcomes in endometrial cancer Gynecologic Oncology. 133: 132-133. DOI: 10.1016/J.Ygyno.2014.03.346 |
0.395 |
|
| 2014 |
Hu W, Liu T, Ivan C, Huang J, Dalton H, Previs R, Nick A, Lopez-Berestein G, Coleman R, Sood A. Selective activation of Notch3 in high-grade serous ovarian cancer Gynecologic Oncology. 133: 115. DOI: 10.1016/J.Ygyno.2014.03.304 |
0.439 |
|
| 2014 |
Davis AN, Ivan C, Previs RA, Dalton HJ, Bottsford-Miller JN, Zand B, Coleman RL, Baggerly KA, Sood AK. Hitting the right mark: Nonoverlapping Notch and PI3K alterations in ovarian cancer Gynecologic Oncology. 133: 96. DOI: 10.1016/J.Ygyno.2014.03.256 |
0.456 |
|
| 2014 |
Matsuo K, Yoshino K, Nishimura M, Hiramatsu K, Banzai C, Sheridan TB, Hasegawa K, Shiki Y, Roman LD, Sood AK. Impact of lymphovascular space invasion (LVSI) on survival of stage I epithelial ovarian cancer Gynecologic Oncology. 133: 85. DOI: 10.1016/J.Ygyno.2014.03.227 |
0.398 |
|
| 2014 |
Davis AN, Lin YG, Previs RA, Dalton HJ, Stone RL, Bottsford-Miller JN, Zand B, Coleman RL, Sood AK, Taylor M. A dose a day keeps the cancer away: Metronomic albumin-bound paclitaxel and topotecan has potent antitumor activity in ovarian cancer Gynecologic Oncology. 133: 71. DOI: 10.1016/J.Ygyno.2014.03.191 |
0.445 |
|
| 2014 |
Dalton HJ, Reusser NM, Zien A, Previs RA, Rupaimoole R, Zand B, Bottsford-Miller JN, Nick AM, Coleman RL, Sood AK. Not your mother's bisphosphonate: Targeting angiogenesis in ovarian cancer Gynecologic Oncology. 133: 42. DOI: 10.1016/J.Ygyno.2014.03.122 |
0.443 |
|
| 2014 |
Nick AM, Ramirez PT, Rangel KM, Schmeler KM, Soliman PT, Burzawa JK, Kodama M, Lu KH, Coleman RL, Sood AK. Launching personalized surgical therapy for advanced ovarian cancer Gynecologic Oncology. 133: 28. DOI: 10.1016/J.Ygyno.2014.03.089 |
0.411 |
|
| 2014 |
Tucker S, Gharpure K, Herbrich S, Nick A, King E, Coleman R, Guenthoer J, Dalton H, Baggerly K, Sood A. Molecular predictors of residual disease in patients with ovarian cancer Gynecologic Oncology. 133: 25. DOI: 10.1016/J.Ygyno.2014.03.081 |
0.354 |
|
| 2014 |
Bottsford-Miller JN, Taylor M, Dalton HJ, Stone RL, Nick AM, Davis AN, Zand B, Previs RA, Afshar-Kharghan V, Sood AK. More is not always better: Thrombocytosis contributes to impaired chemotherapy response in ovarian cancer Gynecologic Oncology. 133: 20-21. DOI: 10.1016/J.Ygyno.2014.03.071 |
0.438 |
|
| 2014 |
Bottsford-Miller JN, Taylor M, Dalton HJ, Stone RL, Nick AM, Davis AN, Zand B, Previs RA, Afshar-Kharghan V, Sood AK. Wound healing gone awry: Role for platelets in tumor growth after antiangiogenic therapy Gynecologic Oncology. 133: 19. DOI: 10.1016/J.Ygyno.2014.03.068 |
0.305 |
|
| 2013 |
Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Toombs JE, ... ... Sood AK, et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell. 155: 552-66. PMID 24243015 DOI: 10.1016/J.Cell.2013.09.041 |
0.383 |
|
| 2013 |
Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. Plos One. 8: e79167. PMID 24236104 DOI: 10.1371/Journal.Pone.0079167 |
0.496 |
|
| 2013 |
Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, ... ... Sood AK, et al. Targeting SRC and tubulin in mucinous ovarian carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6532-43. PMID 24100628 DOI: 10.1158/1078-0432.Ccr-13-1305 |
0.328 |
|
| 2013 |
Lutgendorf SK, Slavich GM, Degeest K, Goodheart M, Bender D, Thaker PH, Penedo F, Zimmerman B, Lucci J, Mendez L, Collins K, Sood AK. Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients. Gynecologic Oncology. 131: 667-73. PMID 24096110 DOI: 10.1016/J.Ygyno.2013.09.025 |
0.383 |
|
| 2013 |
Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in cancer therapy. Journal of Drug Targeting. 21: 904-13. PMID 24079419 DOI: 10.3109/1061186X.2013.837469 |
0.399 |
|
| 2013 |
Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, ... ... Sood AK, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. Journal of the National Cancer Institute. 105: 1485-95. PMID 24062525 DOI: 10.1093/Jnci/Djt210 |
0.432 |
|
| 2013 |
Shinn EH, Lenihan DJ, Urbauer DL, Basen-Engquist KM, Valentine A, Palmero L, Woods ML, Patel P, Nick AM, Shahzad MM, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AK. Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 2102-9. PMID 24045927 DOI: 10.1158/1055-9965.Epi-13-0625 |
0.462 |
|
| 2013 |
Tekedereli I, Alpay SN, Akar U, Yuca E, Ayugo-Rodriguez C, Han HD, Sood AK, Lopez-Berestein G, Ozpolat B. Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer. Molecular Therapy. Nucleic Acids. 2: e121. PMID 24022053 DOI: 10.1038/Mtna.2013.45 |
0.426 |
|
| 2013 |
Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, ... ... Sood AK, et al. Tumour angiogenesis regulation by the miR-200 family. Nature Communications. 4: 2427. PMID 24018975 DOI: 10.1038/Ncomms3427 |
0.355 |
|
| 2013 |
Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, ... ... Sood AK, et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discovery. 3: 1302-15. PMID 24002999 DOI: 10.1158/2159-8290.Cd-13-0159 |
0.404 |
|
| 2013 |
Nagaraja AS, Sadaoui NC, Lutgendorf SK, Ramondetta LM, Sood AK. β-blockers: a new role in cancer chemotherapy? Expert Opinion On Investigational Drugs. 22: 1359-1363. PMID 23919278 DOI: 10.1517/13543784.2013.825250 |
0.375 |
|
| 2013 |
Thaker PH, Sood AK, Ramondetta LM. Importance of adrenergic pathways in women's cancers Criminal Behaviour and Mental Health. 13: 145-154. PMID 23912486 DOI: 10.3233/Cbm-130324 |
0.368 |
|
| 2013 |
Melhem-Bertrandt A, Sood AK. Adrenergic signaling and cancer: Deciphering the connections Cancer Biomarkers. 13: 131-132. PMID 23912484 DOI: 10.3233/Cbm-130333 |
0.386 |
|
| 2013 |
Gharpure KM, Sood AK. Neighborhood matters: Response to EZH2 methyltransferase inhibitors Cell Cycle. 12: 2345. PMID 23887388 DOI: 10.4161/Cc.25775 |
0.44 |
|
| 2013 |
Masiero M, Simões FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, ... ... Sood AK, et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 24: 229-41. PMID 23871637 DOI: 10.1016/J.Ccr.2013.06.004 |
0.439 |
|
| 2013 |
Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. Poor survival with wild-type TP53 ovarian cancer? Gynecologic Oncology. 130: 565-9. PMID 23800698 DOI: 10.1016/J.Ygyno.2013.06.016 |
0.373 |
|
| 2013 |
Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Mælandsmo GM, Kong H, Zhang T, Jerónimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, et al. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: E2572-81. PMID 23798432 DOI: 10.1073/Pnas.1304318110 |
0.363 |
|
| 2013 |
Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Liu J. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 23: 815-22. PMID 23669443 DOI: 10.1097/Igc.0B013E31828F7A24 |
0.38 |
|
| 2013 |
Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, ... ... Sood AK, et al. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia (New York, N.Y.). 15: 502-10. PMID 23633922 DOI: 10.1593/Neo.121412 |
0.394 |
|
| 2013 |
Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, ... ... Sood AK, et al. ATP11B mediates platinum resistance in ovarian cancer. The Journal of Clinical Investigation. 123: 2119-30. PMID 23585472 DOI: 10.1172/JCI65425 |
0.367 |
|
| 2013 |
Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J. Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia (New York, N.Y.). 15: 409-20. PMID 23555186 DOI: 10.1593/Neo.121228 |
0.449 |
|
| 2013 |
Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Frontiers in Oncology. 3: 58. PMID 23519775 DOI: 10.3389/Fonc.2013.00058 |
0.452 |
|
| 2013 |
Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, ... ... Sood AK, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 23: 186-99. PMID 23410973 DOI: 10.1016/J.Ccr.2012.12.020 |
0.337 |
|
| 2013 |
Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JS. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology (Baltimore, Md.). 58: 182-91. PMID 23389994 DOI: 10.1002/Hep.26310 |
0.385 |
|
| 2013 |
Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, ... ... Sood AK, et al. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1806-15. PMID 23386691 DOI: 10.1158/1078-0432.Ccr-12-2764 |
0.441 |
|
| 2013 |
Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer Nature Reviews Clinical Oncology. 10: 211-224. PMID 23381004 DOI: 10.1038/Nrclinonc.2013.5 |
0.418 |
|
| 2013 |
Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, ... ... Sood AK, et al. Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nature Communications. 4: 1403. PMID 23360994 DOI: 10.1038/Ncomms2413 |
0.69 |
|
| 2013 |
Nagaraja AS, Armaiz-Pena GN, Lutgendorf SK, Sood AK. Why stress is BAD for cancer patients. The Journal of Clinical Investigation. 123: 558-60. PMID 23348736 DOI: 10.1172/Jci67887 |
0.696 |
|
| 2013 |
Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 809-20. PMID 23344261 DOI: 10.1158/1078-0432.Ccr-12-2736 |
0.487 |
|
| 2013 |
Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecologic Oncology. 129: 86-91. PMID 23321064 DOI: 10.1016/J.Ygyno.2013.01.006 |
0.356 |
|
| 2013 |
Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecologic Oncology. 128: 506-11. PMID 23200915 DOI: 10.1016/J.Ygyno.2012.11.029 |
0.446 |
|
| Show low-probability matches. |